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ABSTRACT OF DISSERTATION
EVALUATION OF THE SUSCEPTIBILITY AND HUMORAL IMMUNE RESPONSE
OF FOALS TO RHODOCOCCUS EQUI INFECTION

While Rhodococcus equi (R. equi) remains the most common cause of subacute or
chronic granulomatous bronchopneumonia in foals, development of a relevant model to
study this bacterium has proven difficult. As a result, the reasons for the underlying foal’s
susceptibility to this disease are not well understood. Furthermore, data regarding the
immune response of foals to R. equi infection remains controversial. We hypothesized
that foals are susceptible to R. equi early in life and that this susceptibility decreases with
age. Also, we hypothesized that specific subclasses of IgG antibodies to the virulenceassociated protein of R. equi, VapA, predict the outcome of exposure.
The objectives of this study were: (1) to develop an R. equi challenge model that
resulted in slow progressive disease in some foals as well as spontaneous regression of
lesions in others, (2) using the developed model, to investigate the age-related
susceptibility of young foals to R. equi, (3) to describe the humoral immune response of
foals following experimental challenge and natural infection.
The use of a low dose of R. equi to challenge neonatal foals resulted in slow,
progressive disease characterized by pulmonary abscessation and spontaneous regression
in approximately 50% of the foals. When this low dose was used in 1, 2 or 3-week-old
foals, a marked decrease in disease susceptibility was observed as the foals aged. The
immunological responses seen after experimental challenge reflect those observed after

natural infection. While there was a significant increase of VapA-specific IgG and IgG
subclasses over time in both pneumonic and healthy foals, use of VapA-specific IgG(T)
showed good sensitivity and specificity when used as a diagnostic tool for R. equi
pneumonia.
In summary, this study shows that foal susceptibility to R. equi occurs early in life
and decreases with age. Whereas all foals developed VapA-specific IgG antibodies postexposure, IgG(T) appeared to be predictive of infection.
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CHAPTER 1
LITERATURE REVIEW AND RESEARCH OBJECTIVES

Rhodococcus equi (R. equi), is the most devastating cause of subacute or chronic
bacterial pneumonia in foals less than 6 months of age 1. Adult horses are resistant to R.
equi infection unless they are immunocompromised, but little is known about the reason
for the unique susceptibility of foals to this infection. This disease has a significant
financial impact in the equine industry worldwide because of its high incidence, the lack
of a vaccine and the presence of the bacteria in the soil

2,3

. This bacterium also affects

other species such as pigs 4, cattle 5 goats 6 and immunocompromised humans 7.

The bacterium
Rhodococcus equi, a Gram-positive coccobacillus, is an aerobic, facultative
intracellular pathogen of macrophages. It belongs to the mycolata group of the genus
Actinobacteria and is characterized by the presence of an outer cell capsule; a mycolic
acid-containing glycolipid barrier that is thought to protect the cell wall from the immune
system 8. Mycolic acids are linked to the arabinogalactan-peptidoglycan layer of the cell
wall by covalent links and form a hydrophobic barrier that protects the bacterium 8. Some
components of this lipid barrier may also play a role in pathogenesis. Mutant strains of R.
equi lacking an enzyme required for elongation of long chain mycolic acids (KasA) have
decreased capacity to prevent phagolysosome formation

9

. As a coprophilic soil

saprophyte, this organism persists and is widely spread in the soil, however, not all
strains are pathogenic. Virulent R. equi carries a large circular plasmid (85-90kb), which
contains a pathogenicity island of around 27 kb with genes encoding 7 virulenceassociated proteins (VapA, VapC to H)

10

. Only vapA, which encodes the 15-17 kDa

1

temperature inducible surface–expressed lipoprotein VapA, is necessary for virulence

11

as vapA- strains of R. equi cannot replicate in macrophages or cause pneumonia in foals
12,13

. Moreover, the type of plasmid possessed determines the bacterium’s host specificity.

Unlike R. equi from horses that possess vapA, isolates from pigs carry vapB plasmid
(pVAPB) while that from bovines have a different plasmid, pVAPN, negative for pVAPA
and pVAPB (“N” standing for no-A no-B) 14.

Pathogenesis in foals
The pathogenesis of R. equi in foals is not well understood but the gastrointestinal
and respiratory tracts are known routes of infection 5,15. Inhalation is considered the major
route of pulmonary infection

16

. Once inhaled, R. equi is taken up by the alveolar

macrophage either by the CR3 (Mac-1) or mannose receptors

17,18

. Virulent R. equi

survives inside the phagocytic vacuole due to its ability to alter the acidification process
19,20

; but the exact mechanism of this process has not been elucidated. Intracellular

replication of R. equi results in macrophage necrosis, infection of new macrophages and
pyogranulomatous inflammation

21

. The incubation period of R. equi after inhalation is

unknown. Factors such as the amount of virulent bacteria present, the age of the foal and
the host defense mechanisms likely affect its outcome 22. Oral exposure also occurs early
in the foal’s life

23

but little is known about its role in development of disease. In one

study, oral administration of pathogenic R. equi protected foals against experimental
challenge 24.

Clinical signs
The typical presentation of R. equi in foals is granulomatous bronchopneumonia,
22,25

though extrapulmonary disorders occur in more than half of the affected foals
2

25,26

.

Pneumonia develops insidiously and clinical signs are usually seen between 3-24 weeks
of life, with the majority of foals showing signs before 16 weeks of age

22

. The slow

spread of the infection along with the remarkable ability of foals to compensate for
progressive loss of pulmonary function complicates early diagnosis. Early disease is
characterized by fever, lethargy and cough 27. Anorexia, tachypnea, increased respiratory
effort and tachycardia appear as the disease progresses

27

. Subacute pneumonia, which

carries poor prognosis, is seen in a small percentage of foals and is characterized by
respiratory distress and fever 28. Extrapulmonary R. equi infections, while reported to be
present in 50% of the cases

25,26

can be difficult to diagnose and many are only found

during necropsy. Survival was lower among foals with extrapulmonary infections

26

.

Granulomatous enterotyphylocolitis, abscessation of mesenteric or other abdominal
lymph nodes and peritonitis are the most common abdominal presentations

26

.

Interestingly, foals with rhodococcal pneumonia rarely show signs of intestinal disease
25,26

. Synovitis, which presents as effusion of one or more joints, is seen in a third to a

fourth of the foals with R. equi infection 26.

Diagnosis in foals
Currently,

the

recommendation

for

definitive

diagnosis

of

R.

equi

bronchopneumonia is bacteriologic culture or amplification of the vapA gene by PCR
from a tracheobronchial aspirate obtained from a foal with either clinical signs of lower
respiratory tract disease, cytological evidence of septic airway inflammation, and/or
radiographic or ultrasonographic evidence of bronchopneumonia

29

. However,

tracheobronchial aspiration is not recommended for foals with severe respiratory distress
30

. While this approach can be used to confirm clinical cases, identification of early
3

30

infection before clinical signs become apparent remains a challenge

. Thoracic

ultrasonography has been used as an early screening method for R. equi infection

31

.

When used routinely on endemic farms, ultrasound overestimates the true incidence of
clinically significant disease and results in unnecessary antibiotic use

32

. While the

majority of foals have ultrasonographically visible lesions, many of these foals
spontaneously recover without the aid of treatment and never develop clinical disease
2,32,33

. These findings, coupled with the fact that macrolide and rifampin resistance has

increased worldwide,

34,35

highlights the need for diagnostic tools capable of detecting

acute infection.

The lack of an appropriate research model
Prior to the widespread use of diagnostic imaging, clinical signs were typically
observed beginning at 2 months of age

25

. This timing coincided with the waning of

maternal antibodies and was presumed to account for disease susceptibility. However,
epidemiological evidence indicates that foals are infected shortly after birth

36-38

, though

it is unclear how long foals remain susceptible to R. equi. It is also unclear why only a
few foals develop clinical signs while the majority recovers uneventfully. This lack of
information is in part due to the absence of a relevant challenge model for this disease in
foals. A large portion of what is known about R. equi is based on studies performed in
mouse 39,40, although mice are naturally resistant to R. equi infection and effectively clear
the bacteria after IV or intranasal challenge 41. Moreover, the spleen and liver, instead of
the lungs, are the target organs in mice after systemic infection
piglets

44

42

. Guinea pigs

43

and

have also been used, but neither developed classical pyogranulomatous

pneumonia after experimental challenge, though the role of virulence-associated plasmid

4

was not fully appreciated when these studies were performed. Even in foals, most studies
report acute, severe pneumonia characterized by large areas of pulmonary consolidation,
requiring humane euthanasia 2–3 weeks after intrabronchial or intratracheal challenge
because of the severity of pneumonia

45,46

. This accelerated disease progression is likely

due to the large doses of R. equi used for the challenges

47

and does not reflect what is

seen in the field. An improved model of R. equi infection in foals that results in
progression of disease similar to that observed after natural exposure is needed to better
understand the age-related as well as the individual susceptibility to this disease.
Moreover, such model will allow for evaluation of different treatments and prophylactic
methods.

The lack of effective prophylactic measures
Currently, a vaccine to prevent R. equi does not exist and farms with an endemic
problem attempt to prevent infections by other means.

The method of choice is

prophylactic IV administration of R. equi-specific hyperimmune plasma (HIP) shortly
after birth; which may be repeated 4-8 weeks later 48.
Administration of HIP appeared to protect foals from development of disease in
some field studies

28,48-50

showed no positive effect

and after experimental challenge;
53-55

51,52

however, other studies

. Further, when a control, untreated group was included,

HIP failed to prevent pneumonia or decrease lesion size or length of treatment in a field
study

56

. Results from field studies should be interpreted with caution because of

limitations such as lack of untreated control foals,
incidence

48-50

48,50

, lack of definitive diagnosis of disease

year-to-year variation in disease
49

, variability in age at plasma

administration 49,50, and differences in volume and frequency of plasma administered 49.
5

While experimental infection provides a more controlled environment to evaluate
HIP efficacy, the large challenge doses often used may have overwhelmed the protective
effects of plasma

52-54

. Other confounders in these models are the age of the foal at the

time of administration of HIP and at challenge,
the extent of exposure

49,50,53

the route and dose of infection and

57

. As epidemiological and experimental data indicates foals are

most susceptible to infection within the first few weeks of life, 36,37,58 early administration
is critical since HIP appears to be ineffective after infection has occurred 59.
To date, the protective component of HIP remains uncertain

53

. Plasma provides

antibodies along with other immune modulators which may enhance the humoral effector
mechanism against this infection
their opsonic activity

15,51,61,62

60

. Antibodies are thought to be important because of

. Opsonins attach to bacteria and to specific receptors on

phagocytic cells enhancing phagocytosis

15

. It is proposed that these antibodies diffuse

into the airway opsonizing R. equi before it reaches the intracellular compartment

63

.

Entry of R. equi into macrophages mediated by macrophage Fc receptors following
antibody binding leads to enhanced bacterial killing instead of survival as seen after entry
via the CR3 receptor

15,17,51,64

. Antibodies have been shown to be beneficial against R.

equi infection in vitro. Plasma from horses vaccinated with R. equi and from infected
foals increased the phagocytic activity of their neutrophils 15,60,61,64,65 and macrophages as
well as their oxidative burst activity and TNF-α production

63

. Further, opsonizing

activity of serum to R. equi increased after vaccination with VapA and this opsonizing
activity was transferred from the vaccinated mares to their foals

66

. The phagocytic

activity of foal’s neutrophils was similar to that of adult’s when these cells were
incubated with adult horse serum. This shows that foal neutrophil function depends on

6

humoral factors, which may change with age, rather than on neutrophil maturation

60

. In

this regard, IgG antibodies are considered important opsonins and they account for 80%
of the total IgG repertoire

67

. New terminology has been proposed for equine IgG

subclasses (IgG1 to IgG7) based on the IgG heavy chain constant gene region 68. In spite
of this, the new nomenclature has not been widely embraced likely as a result of the
unavailability of reagents and the fact that commercially available reagents are still sold
using the original nomenclature. As a result, original nomenclature will be used
throughout the rest of this document. A table comparing the original and current
nomenclature is provided (Appendix, supplementary table 1.).
In the adult horse, IgG(T), IgGa and IgGb activate complement and strongly
stimulate a respiratory burst from peripheral blood leucocytes after binding to the Fcγ
receptor

69

. These antibodies are produced in a limited fashion in neonatal foals

70-72

.

Endogenous production of IgGa and IgG(T) is only evident around 4-5 weeks of age and
IgGb endogenous synthesis is not significant until foals are 8-12 weeks of age,

24,70,72,73

however, foals have been shown to synthetize all IgG subclasses earlier if the correct
stimulus is provided

74

. This relative deficiency of IgG may play a role in the

development of R. equi pneumonia 75 and is reflected in the humoral response of foals to
vaccination. While vaccine-specific IgGa and IgG(T) significantly increased after 3-dayold foals were vaccinated twice at 21 day intervals using a cattle product, a significant
increase in vaccine-specific IgG and IgGb was evident only when 3-month-old foals were
vaccinated. Overall, the response of the foals was lower than that seen in adult horses 76.
Since the half-life of immunoglobulins after IV administration ranges from 30-90 days,
50,67

and opsonizing activity is retained after thawing,

7

60

HIP is an important source of

antibodies until endogenous production of IgG occurs. Moreover, unlike antibodies
passively acquired by colostrum that depend on humoral response of vaccinated mares,
quality of colostrum and ability of foal to nurse, HIP administration could provide a
standardized amount of IgG to the foals. However, significant variability was seen in R.
equi specific antibodies after HIP administration to foals 50.
Thus, despite its widespread use, convincing evidence to support HIP plasma
efficacy is lacking. Further, the minimum effective dose to prevent R. equi pneumonia is
currently unknown. Many factors such as infectious challenge, host susceptibility, age,
weight, sex and farm management, among others, likely come into play during natural
infections

49,58

and these may have an effect on the HIP dose required for protection. In

addition, little is known about the quantity or quality of specific anti-R. equi antibodies
contained in different plasmas. Moreover, there is no standard protocol for HIP
production. The end plasma product depends on the strain selected for vaccination, the
dose and adjuvant used, and immunogenic factors of the donor 58. Individual horses have
been shown to respond poorly to vaccination to R. equi

48

and significant individual

variation in the opsonic activity was seen amongst plasma donors 60.

The IgG response of foals to R. equi remains unclear
The possible role that each IgG subclass may play in R. equi infections is poorly
defined. This issue is complicated by the contradictory results reported in humoral
response after infection. Rhodococcus equi specific IgG and fecal bacterial
concentrations increased over time in foals beginning at 3-5 until 9 weeks of age as a
result of natural exposure

77,78

. Pneumonic foals had significantly higher R. equi specific

IgG and IgGb than exposed adults

62,77

. Oral and intratracheal inoculation of foals

8

increased R. equi specific IgG,

57

and both IgGa and, surprisingly, IgGb, but not IgG(T),

increased after intrabronchial challenge of neonatal foals

74

. Adults experimentally

challenged with R. equi have been shown to have a predominant increase in IgGa,

62

IgGb 74or both IgGa and IgGb 75. The role of IgG(T) antibodies in R. equi infection is less
understood. Pneumonic foals produced IgG(T) antibodies in response to R. equi and this
response was not seen in adults or exposed healthy foals

62

. The increase in IgG(T) was

significantly higher when a larger R. equi inoculum size rather than a small one was used
to challenge neonatal foals 47. While early studies proposed that IgG(T) couldn’t activate
complement and therefore it was an undesired response to infection,
been shown to be the most potent complement activator in horses

69

62

IgG(T) has since

. Moreover, VapA-

specific IgG(T) increased after oral immunization with virulent R. equi that successfully
protected foals

24

. The role of IgG(T) has been shown to be important in parasitic

infections. Strongylus vulgaris 79,80 and Cyathostome (small strongyle) infections resulted
in a predominant increase of IgG(T) 81. Moreover, the increase seen in IgG(T) correlated
with the intensity of Anoplocephala perfoliata infection intensity in horses 82. IgG(T) was
also the most efficient antibody to neutralize snake venom

83

. It is fairly clear from the

studies described above that further research needs to be conducted in order clarify the
role of IgG and IgG subclasses in the response of foals to R. equi. Such knowledge could
prove useful at the time of diagnosis of this disease.

Serology and diagnosis
Antibody detection using whole R. equi or crude antigen extracts in ELISAs has
been previously evaluated as a screening tool to detect early R. equi infection, but this
method lacked sensitivity due to high background resulting from environmental exposure
9

to this ubiquitous bacterium

30,62,84

. Methods utilizing antibody detection are also

confounded by passively transferred antibodies from colostrum and HIP

85

. Moreover, a

significant overlap in titers exists between pneumonic and clinically normal foals, which
is likely due to subclinical disease

30,86

. In addition, some ELISAs lack the ability to

differentiate responses to pathogenic and non-pathogenic strains of R. equi. As a result,
the specificity of R. equi ELISAs had limited use. Subsequent studies have used a VapAspecific ELISA to evaluate the antibody response after experimental challenge and
natural infection

24,30,75

. While this approach is specific for pathogenic isolates,

87

it was

not useful as a diagnostic tool for rhodococcal pneumonia because clinically healthy foals
also have antibodies to virulent R. equi 30. Moreover, this VapA-specific IgG ELISA has
never been properly validated. Moreover, little is known about the VapA-specific
subclasses IgGa, IgGb and IgG(T) for early diagnosis of pneumonia caused by R. equi.
Thus, despite years of effort, much remains unknown regarding the foal’s
response to R. equi. As an attempt to advance our knowledge, the following hypotheses
(H) and specific aims (SA) are proposed:

H1 - Foals are susceptible to R. equi early in life and this susceptibility decreases with
age.
(SA) 1-Develop an R. equi challenge model that results in slow progressive
disease in some foals as well as spontaneous regression of lesions in others.
(Chapter 2)
(SA) 2-Use this low dose model to investigate the age-related susceptibility of
young foals to R. equi. (Chapter 2)

10

H2 - The VapA-specific IgG subclass response can be used to predict the outcome of
exposure.
(SA) 1- Validate a VapA-specific ELISA for IgG and its subclasses IgGa, IgGb
and IgG(T). (Chapter 3)
(SA) 2- Describe the VapA-specific IgG response of foals following experimental
challenge and natural infection. (Chapter 4)

H3 - Variations in HIP can account for the reported disparate efficacies.
(SA) 1- Describe the variation in VapA-specific IgG and IgG subclasses between
and within commercial R. equi specific HIP. (Chapter 5)
(SA) 2- Determine the effect that HIP variation has on the amount of VapAspecific IgG received by the foals. (Chapter 5)

Copyright © Macarena G Sanz 2014
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CHAPTER 2
THE EFFECT OF BACTERIAL DOSE AND FOAL AGE AT CHALLENGE ON
RHODOCOCUS EQUI INFECTION
Veterinary Microbiology, 2013: 167 (3-4), 623-631

Summary
While Rhodococcus equi remains the most common cause of subacute or chronic
granulomatous bronchopneumonia in foals, development of a relevant model to study R.
equi infection has proven difficult. The objective of this study was to identify a challenge
dose of R. equi that resulted in slow progressive disease, spontaneous regression of lung
lesions and age-dependent susceptibility. Foals less than one-week of age were
challenged intratracheally using either 106, 105, 104, 103 or 102 cfu of R. equi. Two doses
(103 cfu and 106) were used to challenge 2 and 3-week-old, and 3 and 6-week-old foals,
respectively. Physical examination, thoracic ultrasound and blood work were performed.
Foals were euthanized at the end of the study or when clinical signs of pneumonia
developed. All foals were necropsied and their lung lesions scored. Foals challenged
with low concentrations of R. equi developed slow progressive pneumonia and
approximately 50% of the foals recovered spontaneously. Likewise, macroscopic (> 1 cm
diameter) pyogranulomatous lesions were only observed when low doses of R. equi were
used. Clinical pneumonia was not seen after low dose challenge in the 3-week-old foals
or in the 6-week-old foals. This study demonstrates that the use of low doses of R. equi to
challenge neonatal foals provides an improved model for studying this disease.
Furthermore, susceptibility to R. equi infection was shown to diminish early in the foal’s
life, as has been reported in the field.
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Introduction
Rhodococcus equi (R. equi) remains the most devastating cause of subacute or
chronic granulomatous bronchopneumonia in foals less than 5 months of age 88. Because
R. equi is ubiquitous and can be endemic in some farms, it has a major financial impact
on the equine industry 2. Nevertheless, little is also known regarding the reason for the
unique susceptibility of foals to this infection. Prior to the widespread use of diagnostic
imaging, clinical signs were typically observed beginning at 2 months of age

25

. Recent

evidence indicates that foals are likely infected shortly after birth 36,37, though it is unclear
how long foals remain susceptible to R. equi. This lack of information has been due, in
part, to the absence of a relevant challenge model for this disease in foals.
Development of an equine model to study R. equi infection has proven difficult.
A large portion of what is known about R. equi is based on studies performed in mouse
models

39,40

, even though mice are naturally resistant to R. equi infection and effectively

clear the bacteria after IV or intranasal challenge

41

. Moreover, the spleen and liver,

instead of the lungs, are the target organs in mice after systemic infection 42. Guinea pigs
43

and piglets

44

have also been used, but neither develops classical pyogranulomatous

pneumonia after experimental challenge, though the role of virulence-associated plasmid
was not fully appreciated when these studies were performed. Even in foals, most studies
report acute, severe pneumonia characterized by large areas of pulmonary consolidation,
requiring humane euthanasia 2-3 weeks after challenge because of the severity of
pneumonia 46,89. This accelerated disease progression is likely due to the large doses of R.
equi used for the challenges

47

. While R. equi infections in the field may present with a

wide range of lesions, pyogranulomatous pneumonia usually develops insidiously with
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slight increases in respiratory rate and mild fever 1. If not recognized, the disease may
become chronic with clinical signs developing over time

25,90

or it may completely

regress without treatment 2; however, what determines the outcome remains unknown.
An improved model of R. equi infection in foals that results in progression of
disease similar to that observed after natural exposure is needed. Such a model will be
beneficial for the development of vaccines, evaluation of treatment options, and
understanding why some foals develop clinical disease while others recover uneventfully.
The objective of this study was to identify a challenge dose of R. equi which resulted
either in slow developing pyogranulomatous pneumonia in neonatal foals or lesion
regression. In addition, the age susceptibility of foals to R. equi was investigated.

Materials and Methods
Study design
The study was divided into two phases. Initially, foals less than 1 week of age
were used to identify a dose of R. equi that would result in clinical disease as well as
natural regression of lesions without the aid of treatment. Once such a dose was
identified, it was then used to determine the relative susceptibility of foals at 1 to 3 weeks
of age. An additional group of 51 3 and 6-week-old foals were infected using an R. equi
strain (103+) that has been previously used for experimental challenges 51,91 (Appendix,
Supplementary Figure 2.1).
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Foals
Foal of 1-, 2-, 3-, and 6-weeks of age were obtained from the Department of
Veterinary Science’s equine herd. Foals were enrolled in the studies if they had a normal
complete physical exam and thoracic ultrasonography along with adequate passive
transfer of immunoglobulins (>800mg/dl using the SNAP® Foal IgG Test, IDEXX
laboratories Inc, Westbrook, ME). Mares and foals were kept on pasture for the duration
of each study. Each pair (mare and foal) was placed in a stall for a period of 2-3h twice a
week while samples were collected and clinical exams performed. These studies were
approved by the University of Kentucky’s Institutional Animal Care and Use Committee
and Institutional Biosafety Committee.

Challenge (Appendix, Protocol 2.1)

R. equi strain 206 (UKVDL206) was provided by Dr. M. Donahue from the
University of Kentucky Veterinary Diagnostic Laboratory (UKVDL) and R. equi strain
103+ was provided by Bioniche Animal Health. The bacteria were stored as a frozen
stock in 20% glycerol and streaked onto a tryptic soy agar yeast extract (TSAYE) plate
and incubated at 37 ºC for 48h. To prepare the inoculum, a single typical mucoid, creamy
colony was selected from the plate, inoculated into tryptic soy yeast broth (TSBYE) and
incubated at 37 ºC for 48h. Bacterial concentrations were initially estimated based on
optical density (OD) of the culture media using a spectrophotometer at wavelength
600nm and confirmed by serial dilution plating. All the isolates were tested for the
presence of virulence associated plasmid A (VapA) using PCR at the UKVDL. The agar
plates were held at room temperature for an additional 72h at which point colony
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morphology was evaluated. Culture media was serially diluted using PBS to a total
volume of 20 ml to obtain the following total concentration of bacteria: 106, 105, 104, 103
and 102 cfu/ml.
Prior to challenge, mare and foals were brought into stalls and the foals sedated
using a combination of IV xylazine (0.5mg/kg) and butorphanol (0.05mg/kg). A flexible
tube was used to deliver the diluted bacteria (total volume 20ml) to the mid trachea
(intratracheal instillation). The number of foals inoculated with the dose of each R. equi
strain and their ages at challenge are shown in Table 2.1

Table 2.1 R. equi dose (cfu), strains used and age of the foal at challenge (weeks).
Number of foals Dose given (cfu)
R equi strain
Age at challenge (weeks)
6
3
10
UKVDL206
1
5
4
10
UKVDL206
1
4
4
10
UKVDL206
1
3
4
10
UKVDL206
1
2
3
10
UKVDL206
1
3
4
10
UKVDL206
2
3
6
10
UKVDL206
3
5
3
10
103+
3
5
5
10
103+
6

Foal evaluation
After the effects of sedation passed, mares and foals were returned to pasture.
The foals were observed daily for increased respiratory rate or effort, lethargy and
anorexia. Complete physical examinations were performed twice a week after challenge
with UKVDL206 and included heart (HR) and respiratory rates (RR), rectal temperature,
characterization of nasal discharge (absent, serous, muco-purulent or purulent), foal’s
attitude (lethargic, anorexic) and close visual examination of the foal’s joints and eyes
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(aided by a penlight). Respiratory effort was evaluated using a modification of a
previously described scoring system 54 where 0=normal respiratory effort at rest, 1=slight
increased effort at rest and 3=moderate effort at rest.
Bilateral thoracic ultrasonography was performed on the foals receiving
UKVDL206 and was performed prior to challenge and weekly thereafter using a 7.5MHz
linear probe (CTS-7700V-SIUI, Universal Medical System, Inc, Bedford Hills, NY).
Each lung was scored, as reported previously

31

as a means to monitor disease

progression in the foals. Briefly, the maximum diameter (mm) of each lesion was
measured and a score was generated based on the largest lesion found on each foal at a
given time point.
Blood was collected before UKVDL206 inoculation and weekly thereafter by
jugular venipuncture for complete blood cell count (CBC) and fibrinogen with the
analyses being performed at UKVDL. Serum was batched frozen at -20ºC for serum
amyloid A (SAA) evaluation using a previously validated immunoturbidimetric assay

92

at the Department of Pathology, University of Miami Miller School of Medicine, Miami,
FL.

Macroscopic lesions and histopathology
Foals were euthanized at 6 (UKVDL206) or 8 weeks (103+) after challenge or
sooner if they had evidence of bronchopneumonia upon thoracic ultrasonography and any
one of the following: fever (temp >102.5F) for 36h; signs of lower respiratory disease for
12h with any of the following observed; abnormal lung auscultation, crackles, or wheezes
or signs of rattles auscultated in the trachea; tachypnea: >48 breath/minute resting rate,
and increased respiratory effort (characterized by abdominal effort and nostril flaring),
17

bilateral mucopurulent or purulent nasal discharge and productive cough. A board
certified pathologist, blinded to the study design, performed all of the necropsies.
Macroscopic lesions were scored for the foals challenged with UKVDL206 using a
system as previously reported 46. The percentage of normal and abnormal lung was
quantitated for each lung lobe. Individual lobe pneumonia scores were added together to
form a cumulative pneumonia score for each foal that was expressed as a percentage of
total lung involvement. A lung weight/body weight ratio was calculated 54,89.
Representative lung samples were collected for histopathology from the right and
left cranial apical regions, right and left middle and dorsal diaphragmatic regions,
accessory lung lobe, and the tracheobronchial lymph node. Each lung sample was
microscopically graded as to the degree of pyogranulomatous inflammation (0=no
inflammation, 1=<5% affected, 2=5-25% affected, 3=25-50% affected, 4=50-75%
affected, or 5= >75% affected) and distribution of parenchymal necrosis (0=none,
1=focal, 2=multifocal, 3=focally to multifocally extensive, or 4=diffuse). Lymph node
samples were histologically graded based on inflammation (0=no inflammation, 1=mild,
2=moderate or 3=severe) in the capsule and subcapsular trabecular and medullary
sinuses.

Lymph node necrosis determination was based on the distribution of the

necrosis (0=no necrosis, 1=focal, 2=multifocal to coalescing or 3=diffuse). A
histopathologic pneumonia score was generated for each foal by adding the inflammation
and necrosis scores for all lung sections together. Similarly, a cumulative lymph node
score was generated by adding both, the inflammation and necrosis scores.
Four distinct patterns of pneumonia (types A, B, C, and D) were recognized and
classified (Figure 2.1). Type A lesions consisted of large well-demarcated granulomas.
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Microscopically, type A lesions were composed of a central locally extensive necrotic
core of cell debris, acidophilic proteinaceous material, and low numbers of neutrophils
and macrophages. The necrotic core was surrounded by an inner inflammatory layer of
low to moderate numbers of epithelioid macrophages, neutrophils, and lesser numbers of
multinucleated giant cells. Macrophages and multinucleated giant cells contained
occasional phagocytized bacteria. The inner inflammatory layer was surrounded by an
outer fibrovascular tissue capsule that was infiltrated with low to moderate numbers of
lymphocytes, plasma cells, and macrophages. Type B lesions consisted of poorlydemarcated fibrotic nodular regions that replaced and disrupted the normal pulmonary
parenchyma. Nodular regions were microscopically composed of arborizing bands and
sheets of collagen-rich fibrous connective tissue that was infiltrated with low numbers of
epithelioid macrophages, lymphocytes, and plasma cells and occasional multinucleated
giant cells. Entrapped individual bronchioles and alveolar spaces were multifocally
distributed throughout the fibrotic regions. Entrapped airways contained low numbers of
epithelioid macrophages and multinucleated giant cells, occasional lymphocytes and
neutrophils, and small amounts of acidophilic proteinaceous material and cell debris;
associated alveolar spaces were frequently lined by hypertrophied and hyperplastic type 2
pneumocytes. Type C lesions consisted of well-demarcated red, firm, consolidated
regions. Histologically, a majority of alveoli, bronchioles, and bronchi within type C
lesions contained low to moderate numbers of epithelioid macrophages, neutrophils, and
occasional multinucleated giant cells intermixed with small amounts of fibrin, acidophilic
proteinaceous material, and cell debris. Phagocytized bacteria were frequently evident in
macrophages and multinucleated giant cells. Within the inflammatory foci were
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occasional poorly demarcated regions of alveolar septal necrosis. The adjacent pleura and
interstitium were mildly fibrotic and infiltrated with minimal to low numbers of
lymphocytes, plasma cells, and neutrophils. Type D lesions grossly consisted of welldemarcated, small, multifocal to coalescing pyogranulomas. Histopathologically, these
lesions had a central necrotic center composed of cell debris intermixed with low to
moderate

numbers

of

neutrophils,

epithelioid

macrophages,

and

occasional

multinucleated giant cells. Macrophages and multinucleated giant cells often contained
phagocytized bacteria.

The necrotic core was frequently surrounded by a thin to

moderate fibrous connective tissue capsule that was infiltrated with low numbers of
lymphocytes and plasma cells.

Figure 2.1 Macroscopic pulmonary lesions. Left: Type A (well-demarcated granulomas,
arrow) and C (poorly demarcated red, firm, consolidated foci, arrow head). Middle: Type
B lesion (poorly-demarcated tan, firm, arborizing region) Inset: higher magnification of
the boxed region displaying the lesion. Right: Type D lesion (small, multifocal to
coalescing pyogranulomas). The bar represents 2cm.
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Bacteriology
One-cm3 tissue samples were obtained for bacterial culture. Samples were
routinely collected from the cranial apical, middle and dorsal diaphragmatic lung lobes
and from the tracheobronchial lymph node (Supplementary figure 2.2). Abdominal lymph
nodes were also collected for the 1, 2 and 3-week old foals that received the 103 cfu
(UKVDL206) dose. Small sections of tissue were placed into sterile 1.5ml Eppendorf
tubes and homogenized for 3 minutes at 30Hz using a Retsch MM301 Ball Mill (Newton,
PA), as previously described 93. Afterwards, serial dilutions of the supernatants were
performed and aliquots were plated onto TSAYE plates and incubated at 37 ºC for 48h.
The number of colonies/g of tissue was then calculated (Supplementary figure 2.3).
Colonies were observed for typical R. equi characteristics (large, mucoid colonies that
developed a red pigment over a 72h period). Gram stain, PCR identification of the
organism and the presence of VapA were confirmed on selected colonies.

Statistical analysis
Survival times by age and dose groups were compared using Kaplan-Meier
estimates of survival probability, with foals surviving until the end of the study treated as
censored. ANOVA models were used to analyze the relationship between age/dose
groups and necropsy, other histopathology scores and bacteriology data; p-values
reported refer to the global (or “omnibus”) test unless otherwise stated. To estimate
changes in physical examination and blood work measurements over time, rates of
change per week were calculated for each foal by least squares. ANOVA models were
then fit to these slopes to determine associations between age/dose groups and changes in
these measurements over time. Correlations between physical examination/blood work
21

measurements and necropsy scores were also calculated and their significance tested
using linear regression.

Results
For the UKVDL206 challenge, the median age (range) at challenge of the 1-week
old foals (n=18) used for the dose selection portion of the study was 3 days (2-7) and it
was not different between dosage groups (p= 0.52). The median age (range) of the 2week-old foals (n=4) was 12 days (10-14). The median age (range) of the 3-week-old
foals (n= 6) was 19 days (17-21). The median age (range) for those 3 (n=3) and 6-weekold (n=5) foals challenged using R. equi 103+ was 22 (18-24) and 47 (39-54) days,
respectively. All bacterial isolates used to challenge the foals were VapA positive (by
PCR) and developed typical colonies on TSAYE plates.

Thoracic ultrasonography
Ultrasound was only available for the foals challenged using UKVDL206.
Ultrasound images were collected for 2 of 3 foals from the 106 group, 3 of 4 foals from
the 105 group and for all the remaining foals. Pulmonary abnormalities were observed in
all foals after challenge. Ultrasonographic lesions consistent with R. equi pneumonia

94

featuring well-defined hypoechoic nodules (Figure 2.2) were observed in one week old
foals receiving the lower doses whereas large areas of consolidated lung were present in
those foals receiving the higher doses. Lesion size decreased over time in 2 of 4 and 2 of
3 the one-week-old foals that received 103 and 102 cfu, respectively (Figure 2.2). Lesion
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size also decreased over time in 2 of 4 foals challenged at 2 weeks of age and in 4 of 6
foals challenged at 3 weeks of age.

Figure 2.2 Thoracic ultrasonography of a newborn foal challenged with a low dose of R.
equi (102 cfu) obtained at 4 (left), 5 (middle) and 6 (right) weeks of age. A well-defined
circular hypoechoic area is observed in the periphery of the left cranial ventral region of
the lung, consistent with pulmonary abscessation caused by R. equi infection. The lesion
cross sections measured 26.1mm, 17.8mm and 9.3mm at 4,5 and 6 weeks of age
respectively. The ultrasounds were performed using a 7.5 MHz linear probe.

Blood work (Tables 2.2 and 2.3)

Pack cell volume, hemoglobin and red blood cell counts were significantly
different over time between doses (p<0.01), decreasing when high doses of bacteria were
inoculated (104, 105 and 106 cfu). Changes over time between doses were not different
for mean cell volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), WBC, neutrophil or monocyte counts. Lymphocyte
counts were different between doses over time (p=0.02), increasing in foals that received
fewer bacteria. A significant correlation was observed between WBC (p=0.04, R2=0.42),
fibrinogen (p=0.02, R2=0.28) and SAA (p=0.014, R2=0.32) concentration at the time of
euthanasia and necropsy scores on one-week-old foals.
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Clinically significant changes over time were not observed for any of the blood
work parameters evaluated on foals challenged at 2 or 3 weeks of age. Though a
significant correlation was observed between SAA concentration at the time of
euthanasia and necropsy scores (p<0.002, R2=0.64).

Physical examination (Tables 2.4 and 2.5)
There was no significant change in HR or the presence of lethargy between doses
over time. Significant changes over time were observed in RR (p=0.001, R2=0.76),
respiratory effort (p=0.02, R2=0.57) and temperature (p=0.003, R2= 0.69) as well as
worsened lung sounds (p=0.02, R2=0.55) when high doses of bacteria were given. R. equi
associated extrapulmonary lesions, including both ocular and joint abnormalities, were
not observed in any of the foals. Foals assigned higher necropsy scores had significantly
higher respiratory rates (p=0.006, R2=0.38) and temperatures (p<0.0001, R2=0.75) at the
time of euthanasia than those with lower necropsy scores.
Temperature increased (p=0.052, R2=0.41) over time in foals challenged at one
and two weeks of age. Fever was not present in any of the foals challenged at 3-weeks of
age. There were no other significant changes observed over time between ages for any of
the physical exam parameters (Table 1.5). Foals assigned higher necropsy scores had
significantly higher temperature (p<0.001, R2=0.69) at the time of euthanasia than those
with lower necropsy scores.
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Table 2.2 Blood work for each challenge dose of UKVDL206 by time point.*
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Challenge
dose (cfu)

Time
point

PCV
(%)

RBC
(x106cells
/ul)

HGB
(g/dl)

MCV
(g/dl)

MCH (fL)

MCHC
(g/dl)

WBC
(x103cells
/ul)

NT
(x103cells
/ul)

LT
(x103cel
ls/ul)

Mono
(x103cells
/ul)

Fibrinogen
(mg/dl)

SAA
(mg/L)

106

0
1
2

39.9 ± 4.7
33.4 ± 2.7
31.2 ± 2.8

9.6 ± 1.3
8.4 ± 1
8.2 ± 0.2

12.8 ± 1.2
10.7 ± 1
9.8 ± 0.8

41.2 ± 0.7
39.8 ± 4.6
38.0 ± 4.3

13.3 ± 0.6
12.7 ± 1.0
11.9 ± 1.3

32.2 ± 0.8
32 ± 1.2
31.4 ± 0.1

6.8 ± 1.5
10.4 ± 0.6
4.34 ± 0.3

4.4
8.5 ± 0.7
2.6 ± 0.5

1.1
1.6 ± 0.4
1.3 ± 0.3

0.1
0.2 ± 0.1
0.3 ± 0.1

600 ± 0
433 ± 200
850 ± 353

36± 7
36 ± 6
2289 ± 524

105

0
1
2

41.8 ± 6
37.1 ± 4.8
32.6 ± 3.5

10.4 ± 0.7
9.1 ± 0.7
8.3 ± 0.4

13.4 ± 1.5
11.7 ± 1.4
10.3 ± 1.3

39.9 ± 3.5
40.3 ± 2.1
39.1 ± 2.4

12.9 ± 0.7
12.8 ± 0.6
12.3 ± 1.0

32.3 ± 1.1
31.7 ± 0.7
31.6 ± 0.7

7.5 ± 1.8
11.3 ± 2.8
8.5 ± 1.7

4.4 ± 3.3
9.7 ± 2.3
6.8 ± 1.7

0.9 ± 0.8
1.3 ± 0.9
1.2 ± 0.7

0.2 ± 0.2
0.1 ± 0.1
0.3 ± 0.3

400 ± 141
375 ± 125
525 ± 95

80 ± 40
41 ± 11
539 ± 484

104

0
1
2

37.7 ± 4.7
38.6 ± 2.9
35 ± 4.6

9.0 ± 1
9.32 ± 0.8
8.8 ±1

12.2 ± 1.4
12.4 ± 0.7
11.4 ± 1.6

41.7 ± 1.6
41.8 ± 0.9
39.5 ± 0.7

13.6 ± 0.8
13.5 ± 0.6
12.8 ± 0.5

32.5 ± 1.1
32.3 ± 0.8
32.5 ± 0.7

8.1 ± 4.0
8.7 ± 1.2
11.4 ± 4.4

6.5 ± 3.5
6.6 ± 0.7
9.9 ± 4.4

1.3 ± 0.4
1.8 ± 1.2
1.4 ± 0.5

0.1 ± 0.1
0.2 ± 0.1
0.1 ± 0.1

375 ± 189
400 ± 100
475 ± 50

48 ± 10
40 ± 12
96 ± 117

103

0
1
2
3
4
5
6

36.8 ± 5.3
34.6 ± 3.1
38.5 ± 6.4
33.7 ± 3.1
36.4 ± 1.4
36.2 ± 1.8
37.3 ± 1.3

8.8 ± 1
8.4 ± 0.9
9.5 ± 1.6
8.8 ± 1.4
9.6 ± 0.5
9.9 ± 0.1
10.2 ± 0.8

11.9 ± 1.6
11.1 ± 1.1
12.3 ± 2.8
10.7 ± 1.1
11.8 ± 0.1
11.9 ± 0.1
11.9 ± 0.4

41.5 ± 2.4
40.9 ± 2.1
40.2 ± 0.3
38.4 ± 2.5
37.6 ± 1.5
36.4 ± 2.2
36.4 ± 1.4

13.4 ± 0.5
13.1 ± 0.8
12.7 ± 0.8
12.2 ± 0.6
12.2 ± 0.6
12.0 ± 0.2
11.6 ± 0.5

32.3 ± 0.9
32.1 ± 0.5
31.8 ± 2.1
31.7 ± 0.4
32.4 ± 1.1
33.0 ± 1.5
32.0 ± 0.1

8.4 ± 1.0
8.6 ± 2.0
10.8 ± 0.4
9.5 ± 0.8
17.6 ± 5.5
16.2 ± 0.8
11.7 ± 1.0

6.7 ± 0.7
6.8 ± 1.8
8.1 ± 0.8
7.0 ± 0.6
14.4 ± 5.0
13.0 ± 1.0
8.9 ± 2.2

1.4 ± 0.9
1.4 ± 0.5
2.2 ± 0.6
1.9 ± 0.2
2.3 ± 0.7
2.4 ± 0.3
2.5 ± 1.0

0.3 ± 0.2
0.2 ± 0.2
0.5 ± 0.2
0.5 ± 0
0.9 ± 0.3
0.5 ± 0.2
0.1 ± 0

300 ± 163
300 ± 81
350 ± 70
650 ± 70
666 ± 115
400 ± 0
400 ± 141

42 ± 3
34 ± 3
264 ± 331
248 ± 293
308 ± 474
30 ± 8
32 ± 2

102

0
1
2
3
4
5
6
7

36.6
37.6 ± 3.2
37.9 ± 3.2
38.5 ± 2.3
35.2 ± 1.6
37.5 ± 2.5
38.8 ± 3.2
39.1 ± 0.8

8.8
8.6 ± 0.8
9.1 ± 0.8
9.6 ± 0.6
9.0 ± 0.4
9.7 ± 0.6
10.1 ± 0.8
10.5 ± 0.1

11.6
12.0 ± 0.8
12.1 ± 0.8
12.4 ± 0.5
11.3 ± 0.3
12.1 ± 0.6
12.9 ± 1.2
12.8 ± 0.1

41.8
43.4 ± 0.2
41.5 ± 0.2
39.9 ± 0.6
39.0 ± 0.2
38.5 ± 0.1
38.2 ± 0.4
37.3 ± 0.4

13.3
13.8 ± 0.4
13.3 ± 0.4
12.9 ± 0.3
12.5 ± 0.2
12.4 ± 0.2
12.6 ± 0.3
12.2 ± 0.1

31.7
31.9 ± 1.0
32.1 ± 1.0
32.3 ± 1.1
32.1 ± 0.5
32.3 ± 0.6
33.1 ± 0.5
32.8 ± 0.5

7.5
8.9 ± 0.6
7.9 ± 0.6
8.4 ± 2.5
9.1 ± 3.5
9.9 ± 0.6
14.1 ± 1.6
12 ± 1.1

6.3
7.1 ± 1.4
5.6 ± 1.4
5.8 ± 2.8
6.3 ± 2.7
6.9 ± 0.9
11.2 ± 1.4
8.4 ± 1.1

1.1
1.4 ± 0.7
2.0 ± 0.7
2.2 ± 0.4
2.4 ± 0.5
2.8 ± 0.8
2.1 ± 0.4
3.2 ± 0.1

0.2
0.3 ± 0.2
0.2 ± 0.2
0.2 ± 0.2
0.3 ± 0.3
0.2 ± 0.1
0.6 ± 0.2
0.2 ± 0

400
250 ± 200
400 ± 200
400 ± 100
500 ± 100
433 ± 57
300 ± 100
500 ± 141

37 ± 14
31 ± 30
51 ± 30
32 ± 5
72 ± 81
27 ± 2
154 ± 212
38 ± 5

*Results are expressed as average ± standard deviation (SD). SD is not shown when data for <2 foals was available. TP0 represents
the sample collected before challenge (2-7 days of age); thereafter, samples were collected on weekly basis. NT (neutrophils), LT
(lymphocytes), Mono (monocytes), SAA (Serum Amyloid A).

Table 2.3 Blood work for foals challenged using 103 cfu of UKVDL206 at 1, 2 or 3 weeks of age.*
Time
point

PCV
(%)

RBC
(x106cells/
ul)

HGB
(g/dl)

MCV
(g/dl)

MCH
(fL)

MCHC
(g/dl)

WBC
(x103cells/
ul)

NT
(x103cell
s/ul)

LT
(x103cell
s/ul)

Mono
(x103cells/
ul)

Fibrinogen
(mg/dl)

SAA
(mg/L)

1 week

0
1
2
3

36.8 ± 5.3
34.6 ± 3.1
38.5 ± 6.4
33.7 ± 3.1

11.9 ± 1.6
11.1 ± 1.1
12.3 ± 2.8
10.7 ± 1.1

41.5 ± 2.4
40.9 ± 2.1
40.2 ± 0.3
38.4 ± 2.5

13.4 ± 0.5
13.1 ± 0.8
12.7 ± 0.8
12.2 ± 0.6

32.3 ± 0.9
32.1 ± 0.5
31.8 ± 2.1
31.7 ± 0.4

8.4 ± 1.0
8.6 ± 2.0
10.8 ± 0.4
9.5 ± 0.8

8.8 ±1.0
8.4 ± 0.9
9.5 ± 1.6
8.8 ± 1.4

1.4 ± 0.9
1.4 ± 0.5
2.2 ± 0.6
1.9 ± 0.2

0.3 ± 0.2
0.2 ± 0.2
0.5 ± 0.2
0.5 ± 0

300 ± 163
300 ± 81
350 ± 70
650 ± 70

43 ± 3
34 ± 3
264 ± 331
248 ± 293

4

36.4 ± 1.4

11.8 ± 0.1

37.6 ± 1.5

12.2 ± 0.6

32.4 ± 1.1

17.6 ± 5.5

9.6 ± 0.5

2.3 ± 0.7

0.9 ± 0.3

666 ± 115

308 ± 474

5
6

36.2 ± 1.8
37.3 ± 1.3

11.9 ± 0.1
11.9 ± 0.4

36.4 ± 2.2
36.4 ± 1.4

12.0 ± 0.2
11.6 ± 0.5

33.0 ± 1.5
32.0 ± 0.1

16.2 ± 0.8
11.7 ± 1.0

9.9 ± 0.1
10.2 ± 0.8

6.7 ± 0.7
6.8 ± 1.8
8.1 ± 0.8
7.0 ± 0.6
14.4 ±
5.0
13.0 ±
1.0
8.9 ± 2.2

2.4 ± 0.3
2.5 ± 1.0

0.5 ± 0.2
0.1 ± 0

400 ± 0
400 ± 141

30 ± 8
32 ± 2

2 weeks

-1
0
1
2
3
4
5

39.0 ± 5.0
35.7 ± 2.3
33.0 ± 3.1
35.0 ± 3.0
33.5 ± 1.5
34.9 ± 3.9
35.6 ± 3.5

9.8 ± 1.2
8.7 ± 0.8
8.2 ± 1.1
8.9 ± 1.1
8.6 ± 0.3
9.1 ± 1.0
9.4 ± 0.9

12.7 ± 1.8
11.5 ± 0.7
10.8 ± 1.0
11.5 ± 1.2
10.7 ± 0.6
11.3 ± 1.1
11.4 ± 1.1

39.9 ± 0.3
41.3 ± 0.9
40.5 ± 1.5
39.5 ± 1.5
39.0 ± 0.8
38.3 ±0.9
37.8 ± 0.5

13.0 ± 0.3
13.3 ± 0.3
13.2 ± 0.5
12.8 ± 0.3
12.4 ± 0.6
12.4 ± 0.4
12.0 ± 0.2

32.5 ± 0.6
32.3 ± 0.1
32.6 ± 0.2
32.4 ± 0.7
31.8 ± 1.1
32.4 ± 0.6
31.8 ± 0.1

9.7 ±1.6
10.8 ± 4.3
7.7 ± 1.6
9.2 ± 2.6
9.7 ± 4.7
10.5 ± 4.0
10.2 ± 3.3

8.5 ± 1.9
9.8 ± 4.8
6.5 ± 1.1
7.1 ± 1.6
7.8 ± 3.9
8.8 ± 3.5
7.9 ± 3.0

0.9 ± 0.2
0.9 ± 0.5
1.0 ± 0.5
1.5 ± 0.6
1.4 ± 0.3
1.4 ± 0.6
1.9 ± 0.5

0.2 ± 0
0.1 ± 0
0.1 ± 0.1
0.4 ± 0.7
0.4 ± 0.5
0.3 ± 0.1
0.4 ± 0.2

300 ± 0
400 ± 0
375 ± 50
500 ± 230
475 ± 95
450 ± 100
450 ± 57

27 ± 17
26 ± 9
89 ± 97
125 ± 167
13 ± 7
52 ± 63
12 ± 3

3 weeks

-2
-1
0
1
2
3
4
5

36.2 ± 3.1
35.6 ± 3
36.6 ± 2.4
35.5 ± 1.3
35.9 ± 3.4
36.7 ± 3.2
40.8 ± 9.9
38.1 ± 3.0

8.7 ± 0.7
8.7 ± 0.8
9.1 ± 0.5
9.1 ± 0.2
9.4 ± 0.9
9.8 ± 0.8
10.9 ± 2.4
10.2 ± 0.7

12.1 ± 1.0
11.2 ± 1.0
11.5 ± 0.7
11.4 ± 0.4
11.5 ± 1.1
11.8 ± 1.2
13.1 ± 3.3
12.3 ± 0.9

41.6 ± 1.7
40.3 ± 2.5
40.2 ± 2.5
39.0 ± 1.9
38.4 ± 1.5
37.7 ± 1.8
37.7 ± 1.5
37.3 ± 1.4

13.8 ± 0.3
13.0 ±1.0
12.6 ± 0.6
12.5 ± 0.6
12.4 ± 0.6
12.2 ± 0.7
12.1 ± 0.4
12.1 ± 0.4

33.2 ± 0.7
32.0 ± 1.1
31.5 ± 0.6
32.0 ± 1.2
32.2 ± 0.9
32.2 ± 0.7
32.1 ± 1.0
32.4 ± 0.7

8.2 ± 0.7
9.7 ± 2.9
9.1 ± 1.8
10.9 ± 3.4
10.9 ± 2.7
12.5 ± 1.8
11.2 ± 3.3
11.8 ± 2.5

6.6 ± 0.9
8.1 ± 3.2
6.9 ± 1.7
8.6 ± 3.2
8.4 ± 2.3
9.1 ± 1.3
8.0 ± 3.2
7.3 ± 2.1

1.3 ± 1.0
1.4 ± 0.5
1.9 ± 0.5
2.1 ± 0.4
2.1 ± 0.6
3.2 ± 0.8
2.7 ± 1.1
4.0 ± 0.7

0.2 ± 0.2
0.2 ± 0.1
0.3 ± 0.2
0.2 ± 0.1
0.4 ± 0.4
0.2 ± 0.1
0.4 ± 0.3
0.6 ± 0.4

240 ± 114
380 ± 83
416 ± 40
466 ± 81
400 ± 167
450 ± 105
433 ± 51
400 ± 154

45 ± 52
178 ± 309
24 ± 5
24 ± 4
19 ± 5
17 ± 6
20 ± 9
16 ± 5
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Age at
infection

* The results are presented as average ± standard deviation (SD). TP0 represents the sample collected before challenge; thereafter,
samples were collected on weekly basis. TP-1 and TP-2 represent samples collected one and two weeks prior to challenge,
respectively. NT (neutrophils), LT (lymphocytes), Mono (monocytes), SAA (Serum Amyloid A).

Table 2.4 Physical exam results for foals challenged using different doses of
UKVDL206 at one week of age.*
Challenge dose
(cfu)

Time
point

Heart rate
(beats/min)

Respiratory rate
(breaths/min)

Temperature
(°C)

106

0
1
2

83 ± 9
87 ± 25
83 ± 9

35 ± 7
49 ± 16
35 ± 7

38.7 ± 0.7
39.3 ± 0.8
38.6 ± 0.7

105

0
1
2

93 ± 24
84 ± 15
76 ± 13

41 ± 13
47 ± 13
61 ± 18

38.5 ± 0.2
38.8 ± 0.4
39.5 ± 0.5

104

0
1
2

94 ± 14
88 ± 18
73 ± 14

45 ± 12
47 ± 12
50 ± 16

38.4 ± 0.3
38.7 ± 0.3
39.2 ± 0.7

103

0
1
2
3
4
5

104± 33
90 ± 16
76 ± 27
59 ± 28
83 ± 31
84 ± 12

54 ± 14
48 ± 14
42 ± 6
45 ± 9
42 ± 4
36 ± 11

38.6 ± 0.2
38.6 ± 0.2
38.6 ± 0.2
38.9 ± 0.5
38.5 ± 0.1
38.6 ± 0.2

102

0
1
2
3
4
5

102± 20
78 ± 21
79 ± 22
63 ± 13
66 ± 14
60 ± 12

55 ± 6
47 ± 15
39 ± 3
39 ± 6
37 ± 3
40 ± 7

38.4 ± 0.5
38.7 ± 0.1
38.3 ± 0.5
38.5 ± 0.6
38.5 ± 0.3
38.6 ± 0.1

*Exams were performed twice weekly and the results are presented as average ±
standard deviation for each week. TP0 represents the exams performed before
challenge.
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Table 2.5 Physical exam results for foals challenged using 103 cfu of UKVDL206 at 1,
2 or 3 weeks of age.*
Age at
challenge

Time point

Heart rate
(beats/min)

Respiratory rate
(breaths/min)

Temperature
(°C)

1 week

0
1
2
3
4
5

104 ± 33
90 ± 16
76 ± 27
59 ± 28
83 ± 31
84 ± 12

54 ± 14
48 ± 14
42 ± 6
45 ± 9
42 ± 4
36 ± 11

38.6 ± 0.2
38.6 ± 0.2
38.6 ± 0.2
38.9 ± 0.5
38.5 ± 0.1
38.6 ± 0.2

2 Weeks

-1
0
1
2
3
4
5

80 ± 19
75 ± 9
61 ± 12
61 ± 22
55 ± 12
55 ± 11
65 ± 10

53 ± 11
42 ± 7
34 ± 5
35 ± 9
34 ± 7
30 ± 14
28 ± 15

38.5 ± 0.2
38.6 ± 0.4
38.5 ± 0.3
38.5 ± 0.3
38.3 ± 0.5
38.2 ± 0.6
38.2 ± 0.4

3 weeks

-2
-1
0
1
2
3
4
5
6

88 ± 13
82 ± 19
79 ± 21
66 ± 12
66 ± 11
65 ± 9
56 ± 6
55 ± 10
60 ± 7

37 ± 10
49 ± 11
46 ± 10
34 ± 9
35 ± 12
33 ± 9
33 ± 6
32 ± 7
28 ± 9

38.6 ± 0.5
38.5 ± 0.1
38.3 ± 0.3
38.5 ± 0.2
38.5 ± 0.2
38.5 ± 0.2
38.3 ± 0.2
38.2 ± 0.2
38.2 ± 0.2

* Exams were performed twice a week and the results are presented as average ±
standard deviation of each week. TP0 represents the exams performed before challenge.
TP-1 and TP-2 represent samples collected one and two weeks prior to challenge,
respectively.
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Survival (Figure 2.3)

There was a significant effect of dose on survival (p<0.0001). All foals that
received high doses (106, 105, 104 cfu) of UKVDL206 and half of the foals that
received 103 cfu were euthanized before the end of the study because they developed
clinical sings of pneumonia (increased respiratory rate and effort, respiratory distress,
fever, anorexia, lethargy) thus meeting the euthanasia criteria. The remaining foals
were euthanized at the end of the study. The average (SD) time to euthanasia was 13
(±1) days post-inoculation for the 106 group, 15 (±0) days for 105 group, 17 (±2) days
for 104 group, 33 (±11) days for 103 group and 43 (±0) days (end of the study) for the
102 group.
Half of the foals challenged using UKVDL206 at 1 and 2 weeks of age were
euthanized before the end of the study because they met the criteria for euthanasia.
None of the foals challenged at 3 weeks of age developed clinical signs.
All of the 3-week-old foals challenged using 105 cfu of 103+ met the criteria for
euthanasia prior to the end of the study. By contrast, all the foals challenged at 6 weeks
of age remained clinically normal for the study period. There was a significant effect of
age on survival (p=0.008).
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Figure 2.3 Top left: Survival probability of one-week-old foals challenged using
different doses of R. equi (UKVDL206). There was a significant effect of dose on
survival (P<0.0001). Top right: Survival probability of foals challenged using 103 R.
equi (UKVDL206) at 1, 2 or 3 weeks of age. Bottom: Survival probability of foals
challenged using 105 R. equi (strain 103+) at 3 or 6 weeks of age. There was a
significant effect of age on survival (P<0.008). The “x axis shows the days post
challenge and the “y” axis represents the survival probability of foals after challenge.

Necropsy and histopathology
Macroscopic necropsy (p<0.01), histologic pneumonia (p=0.02) and fibrosis
(p=0.04) scores, and lung weight to body weight ratio (p=0.04) were significantly
higher when a dose of ≥104cfu UKVDL206 was administered. Lymph node
inflammation scores were not different between doses (p=0.16) (Figure 2.4).
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Figure 2.4 A significant association was found between the dose of bacteria used to
challenge and the gross necropsy scores (top left, p<0.01), pneumonia (top right,
p=0.02) and fibrosis histological scores (bottom left, p=0.01) as well as body weight to
lung weight ratio (bottom right, p<0.01). The box plots represent the median, upper and
lower quartiles, while the dots represent the individual data points. Error bars represent
95% confidence intervals.

The macroscopic pneumonia scores and the type of lesions observed varied with
the different doses of UKVDL206 (Figure 2.5). Macroscopic pneumonic lesions were
identified in all of the foals inoculated with high doses of bacteria (106, 105 and 104
cfu). Both, type C and D lesions were evident in these foals in all ventral lung segments
sampled but discrete type D lesions were also occasionally present in all lung segments.
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Macroscopic pneumonic lesions were identified in 3 of 4 foals inoculated using a dose
of 103 cfu. Types A, B and C lesions were observed in these foals. Type A lesions
measured up to 2.5 cm in diameter and were frequently surrounded by type C lesions.
All lesion types were distributed throughout all segments of the lung. Macroscopic
pneumonic lesions were identified in 2 of 3 foals inoculated using a dose of 102 cfu
UKVDL206. Type A and B lesions were observed in the mid-ventral areas of the lung.
Type A lesions measured 1.5 - 3 cm in diameter.

Figure 2.5 Lungs collected at necropsy of foals challenged using 106, 105,104 (left top
to right) and 103 and 102 cfu (bottom left to right), respectively. Cranioventral lung
consolidation (type C lesion) and small nodules (type D lesion) are noted on large areas
of the lungs after high doses of R. equi were administered (gray arrows). Focalized
abscesses (solid arrow) with minimal consolidation are observed when low (103 and 102
cfu) doses were used. The bar represents 2cm.
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The percentage of lung affected (p=0.04) and the degree of tracheobronchial
lymph node inflammation (p<0.01) were significantly lower in older than younger foals
and the lung weight to body weight ratio was significantly (p=0.003) higher for
younger foals. Histological pneumonia (p=0.37) and fibrosis scores (p=0.30) were not
significantly different between different the age groups (Figure 2.6).

Figure 2.6 Top left: Older foals had a significantly (p=0.04) lower percentage of lung
affected and tracheobronchial (TB) lymph node inflammation (p<0.01, top right) than
did younger foals. The lung weight to body weight ratio was significantly (p=0.003)
lower in young than old foals (bottom left).
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Lesions A, B and C were observed in foals challenged on weeks 1 and 2 of age
and the lesions were commonly present and distributed thorough the lungs. Type C
lesions were frequently located adjacent to type A lesions. Lesions type A and B were
most commonly identified in foals challenged at 3 weeks of age with a single welldemarcated type C lesion present in one of the 3-week- old foals.

Bacteriology
When high doses (106 and 105 cfu) of UKVDL206 were inoculated, large
numbers of bacteria per gram of tissue were isolated from all tissue sample locations.
As the dose decreased, significantly lower numbers of bacteria were enumerated per
gram of lung (p=0.027) and tracheobronchial lymph node (p=0.021) tissue and bacterial
isolation was localized to specific lung regions.(Table 2.6) The number of bacteria per
gram of lung tissue was significantly (p=0.022 for UKVDL206 and p=0.036 for 103+)
lower in older foals after challenge with either strain of R. equi (Table 2.7). The number
of bacteria per gram of tracheobronchial lymph node tissue was significantly (p=0.008)
lower on older foals after challenge with UKVDL206.
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Table 2.6 R. equi isolation from standardized lung samples by challenge dose.*
Dose (cfu) Lung
TB LN
106

3.2x107
6.0x106
2.6x106

NA
1.4x107
7.2x105

105

1.1x107
1.4x106

6.5x104
3.5x106

104

1.1x107
2.3x107
3.0x105
5.1x104

7.0x105
3.5x103
1.0x104
1.9x104

103

8.0x103
14
111
1.5x105

574
55
30
4.3x103

102

445
97
24
271
0
274
*Average of 6 lung samples per foal collected at necropsy from one-week-old foals
challenged using different doses of UKVDL206. The results show total cfu/g of tissue
isolated from both lungs (combined) and tracheobronchial (TB LN) lymph node. NA
indicates that sample was not available for analysis.
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Table 2.7 R. equi isolation from standardized lung samples collected at necropsy from
foals challenged at either 1, 2 or 3 weeks of age.*
Age at challenge Lung
TB LN Abd LN
1 week

8003
14
111
157602

574
55
30
4324

NA
0
37
81

2 weeks

1551
28176
0
3

64
22
0
54

40
1
0
2

3 weeks

0
0
0
4
16
0
5
2
0
0
0
0
0
0
0
0
0
0
*Average of 6 lung samples per foal challenged with 103 cfu of UKDVL. The results
show total cfu/g of tissue isolated from both lungs (combined) and the tracheobronchial
(TB LN) and abdominal (Abd LN) lymph nodes. NA indicates that samples were not
available.

Discussion
Consistent with other reports 13,46,95 neonatal foals given large doses ( ≥104 cfu)
of R. equi had to be euthanized because they developed severe acute pneumonia where
consolidation was observed in extensive areas of the lungs.
This acute pneumonia differs from the pyogranulomatous pneumonia that
develops insidiously and is frequently observed on endemic farms

1

.

Clinical

abnormalities were observed in all high dose challenged neonatal foals as they
developed acute pneumonia. As such, there was a correlation between increased
respiratory rate and effort, increased temperature and severity of the pneumonia. Serum
36

fibrinogen was markedly elevated in these foals and the increases were correlated with
the amount of damage to the lung. While elevations of plasma fibrinogen were seen in
foals with pneumonia caused by R. equi, this also occurred in other bacterial
pneumonias and is thus not unique or specific for R. equi 96. Serum amyloid A (SAA),
an acute phase protein and a sensitive marker of inflammation

97

, was significantly

increased over time after challenge and this increase was correlated with the degree of
pneumonia. Others have found that SAA is not helpful for early diagnosis of R. equi
pneumonia

98

but useful in monitoring disease progression

99

, as in this study. Thus,

the clinical changes seen in these foals were consistent with an acute bacterial
pneumonia, though not necessarily that caused by R. equi.
At necropsy, a high lung to body weight ratio was observed in the high dose
foals and in younger foals as pneumonic lungs have been shown to be heavier than
those of normal foals 54,89.
Both type C and D lesions were present in young foals challenged with high
doses of R. equi (UKVDL206 or 103+) whereas field infections usually develop type A
and B lesions

100

. Not surprisingly, R. equi was isolated from all of the lung samples

and tracheobronchial lymph nodes when high doses of R. equi were used. By contrast,
intratracheal administration of 103 cfu of R. equi resulted in half of the foals developing
clinical pneumonia that met our criteria for euthanasia. The remaining foals, as well as
all of the foals receiving 102 cfu, remained clinically normal with evidence of
pulmonary lesion regression upon ultrasound evaluation.

This spontaneous lesion

regression often occurs in foals naturally infected with R. equi

2,32

. The mechanism

responsible for this regression remains unknown. While lymphocyte counts increased
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over time in foals that were challenged with the low dose of bacteria, this is likely an
effect of age as lymphocyte counts increase over time in healthy foals

101

. Overall,

WBC was a poor predictor of disease severity, as has been reported for clinical cases of
rhodococcosis

2,96

. Similarly, serum fibrinogen and SAA were only elevated prior to

necropsy in the clinically affected foals and there was no change in the clinically
normal foals. These results are consistent with the clinical findings seen in field cases
of rhodococcal pneumonia in foals.
At necropsy, the low dose challenged foals presented with one or multiple
coalescing pyogranulomas as can be seen following natural infection

5,25

with R. equi

localizing to specific areas of the lung. Furthermore, arborizing fibrotic foci, type B
lesions, in the foals challenged using low R. equi doses were also seen. The presence of
these characteristic lesions supports the ultrasonographic observations of lesion
regression, consistent with that observed on endemic farms where some foals develop
clinical disease while others remain subclinical

16

or even completely regress without

treatment 2.
Clinical pneumonia did not occur during the observation period in 3-week-old
foals inoculated with 103 cfu (UKVDL206). Moreover, the percentage of affected lung
on these foals and the number of bacteria isolated from multiple sites was significantly
lower than that observed in 1 and 2 week-old foals challenged using the same dose of
R. equi. While all of the 3-week-old foals challenged using 105 cfu (103+) developed
clinical signs of pneumonia, none of the 6-week-old foals did. In addition, the older
foals had significantly lower numbers of bacteria isolated from their lungs. Together,
our results are consistent with field studies indicating young foals are more susceptible
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to infection

36,37

.

The demonstration of spontaneous regression in these foals is

consistent with prior work showing age-related susceptibility to experimental challenge
15

and with recent field studies 2,32.
One of the limitations of this study was the small number of foals used. Thus,

some of the parameters that were evaluated as predictors of disease may not have been
significant because of the lack of power in our analyses. Also, since all foals were
euthanized at the end of the study, it was not possible to determine whether the
subclinical foals would have become clinical or resolved their lesions.
In conclusion, the use of high doses of R. equi to challenge foals resulted in
acute, severe pneumonia characterized by large areas of pulmonary consolidation and
severe pneumonia. Challenge with low doses of R. equi resulted in the development of
insidious disease characterized by pyogranulomatous pneumonia similar to that
observed in clinical cases of R. equi infections. Spontaneous regression of lung lesions
was also observed, as has also been seen on endemic farms. While evidence from field
studies indicates that foals are infected with R. equi shortly after birth, it remained
unclear how long foals remained susceptible. We have demonstrated that foals 3 weeks
and older showed decreased susceptibility to infection.

Copyright © Macarena G Sanz 2014

39

CHAPTER 3
VALIDATION AND EVALUATION OF VapA-SPECIFIC IgG AND IgG
SUBCLASSES ELISAs TO IDENTIFY FOALS WITH RHODOCOCCUS EQUI
PNEUMONIA
Equine Veterinary Journal, in press (2014)

Summary
Rhodococcus equi is a common cause of foal pneumonia; however its diagnosis
remains a challenge for equine veterinarians. While the VapA-specific IgG ELISA has
low sensitivity and specificity for detecting pneumonic foals, little is known about
VapA-specific IgG subclasses. The objective of this study was to evaluate the
performance of VapA-specific ELISA for IgG and its subclasses IgGa, IgGb and
IgG(T) in the early diagnosis of pneumonia caused by R. equi. The VapA-specific
ELISA was validated using serum samples from exposed (n=125) and non-exposed
(n=10) adult horses from Iceland. The diagnostic performance of VapA-specific IgG
and its subclasses was evaluated using banked serum samples from pneumonic (n=21)
and healthy (n=80) foals. Sera from exposed and non-exposed adult horses and from
experimentally challenged and naturally infected foals were used for ELISA validation.
Necropsy and tissue culture records of the last 24 years from the Institute for
Experimental Pathology at the University of Iceland in Keldur, Iceland laboratory were
evaluated to confirm the absence of R. equi cases in Iceland. To evaluate each IgG
assay, a cut-off value was selected based on ROC curve analysis and used to calculate
sensitivity and specificity. The intra and inter-assay coefficient of variation were
calculated for each ELISA. Using sera from Iceland, where R. equi infection has not
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been reported, the VapA-specific IgG ELISA differentiated exposed from non-exposed
horses. When used to identify infected foals, VapA-specific IgG, IgGa and IgGb had no
diagnostic value. In contrast IgG(T) had high sensitivity and specificity. In conclusion,
horses from Iceland are not exposed to VapA+ R. equi and can serve as negative
controls. VapA-specific IgG subclasses, with the exception of IgG(T), are poor
predictors of disease. Further investigation on the use of IgG(T) as a diagnostic tool
under field conditions is needed.
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Introduction
Rhodococcus equi (R. equi), a Gram-positive facultative intracellular pathogen,
is the most devastating cause of pneumonia in foals between 3 weeks and 5 months of
age

1

. Currently, the recommendation for definitive diagnosis of R. equi

bronchopneumonia is bacteriologic culture or amplification of the vapA gene by PCR
from a tracheobronchial aspirate obtained from a foal with either clinical signs of lower
respiratory tract disease, cytological evidence of septic airway inflammation, and/or
radiographic or ultrasonographic evidence of bronchopneumonia

29

. While this

approach can be used to confirm clinical cases, identification of early infections before
clinical signs become apparent remains a challenge. Although thoracic ultrasonography
has been used as an early screening method for R. equi infection; 31 recent studies have
shown that the majority of foals with ultrasonographic lesions will resolve their
infection without treatment 2,32. Thus, ultrasonographic screening overestimates the true
incidence of clinically significant disease and can result in unnecessary antibiotic use.
These findings, coupled with the fact that macrolide and rifampin resistance has
increased worldwide, 34,35 highlights the need for a diagnostic tool capable of detecting
acute infection.
Antibody detection using whole bacterium or crude antigen extraction in
ELISAs has been previously evaluated as a screening tool to detect early R. equi
infection, but this method lacked sensitivity due to antibody production that results
from environmental exposure

30,62,84

. Methods utilizing antibody detection are also

confounded by passively transferred antibodies from colostrum and hyperimmune
plasma

85

. In addition, some ELISAs lack the ability to differentiate between
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pathogenic and non-pathogenic strains of R. equi. Together, these issues limited the
specificity of this approach.
More recent studies have used a VapA-specific ELISA to evaluate the response
after experimental challenge or natural infection

24,30,75,84,102

. The advantage of this

approach is that it is specific for pathogenic isolates containing the virulence-associated
plasmid which encodes the VapA protein 12. While this VapA-specific ELISA is widely
used, little is known about the performance of this test. Therefore, the objective of this
study was to evaluate the VapA-specific ELISA for IgG and its subclasses IgGa, IgGb
and IgG(T) for the early diagnosis of pneumonia caused by R. equi.

Materials and methods
VapA purification (Appendix, Protocol 3.1)
Recombinant VapA protein was produced and purified using an Escherichia
coli strain that contained a VapA plasmid fused to glutathione-S-transferase, as
previously described

51

. The purity of the protein was assessed by sulfate-

polyacrylamide gel electrophoresis (SDS-PAGE).b

Source of reference control sera
Positive and negative control sera were included in each plate. A mare
previously vaccinated with killed VapA+ R. equi was used as the positive control.
Negative control sera included fetal equine serum (FES) and serum obtained from a 4month-old foal with negative necropsy and lung tissue culture for R. equi. The foal
belonged to the University of Kentucky Equine research herd where R. equi pneumonia
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does not routinely occur. In addition, commercially available R. equi specific
hyperimmune plasmas were used to construct standard curves. The standard curves for
VapA-specific IgG, IgGa and IgGb were constructed using one product (ReSolution c)
while a different one (EquiplasRd ) was used for VapA-specific IgG(T) because it had
higher concentration of this IgG subclass. All reference sera were divided into 100µl
aliquots and stored at -20°C until used.

VapA-specific enzyme-linked immunosorbent assay development (Appendix, Protocol
3.2)
The ELISA for VapA-specific IgG was based on previously described methods
62,78

and slightly modified. The VapA, serum and conjugates were titrated to achieve the

optimal concentration using checkerboard titrations (data not shown). Briefly, 96-well
microplatese were coated with recombinant VapA (0.5ug/well) in carbonate bufferf and
allowed to incubate overnight at 4°C. Afterwards, a mixture of blocking buffer
(polyvinyl alcohol [Mowiol 6–98]6 1% [w/v] in distilled water) and phosphate-buffered
(PBS, to a final concentration of 1:1[v/v]) was added. Serum was diluted (1:100) in
PBS with 0.05% Tween-202 (PBST) and added to duplicate wells and incubated at
37ºC for 1h. Either goat anti-horse IgG conjugated with horseradish peroxidase (HRP)g
(1:10,000) or murine anti-IgGa (1:2, CVS48) anti-IgGb (1:5 CVS39) or anti-IgG(T)
(1:2, CVS40) (all hybridomas provided by P. Lunn, North Carolina State University)
were then added and incubated for 1h at 37ºC. The subclass plates were washed and
goat anti-mouse IgG-HRPh (1:2000) was added for an additional hour at 37ºC. Plates
were washed between each step with PBST using an ELISA plate washer (MW
96/384)i. The substrate (3,3’,5,5’-tetra-methylbenzidine, peroxidase substratej) was then
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added for five minutes. The reaction was stopped using stop solutionj. Absorbance was
read at 450nm using an ELISA plate readerb. Results from the test sera were converted
to ELISA units (EU) utilizing a logarithmic trend line from the standard curve
generated for IgG and each subclass 103. A coefficient of determination (r2) of ≥ 0.90 for
the standard curve was required for the results to be considered valid 104.

Validation methods for VapA-specific enzyme-linked immunosorbent assay
To estimate assay repeatability, a total of 12 samples ranging from high (n=4),
intermediate (n=4), low (n=3) and negative (n=1) were selected to evaluate intra-assay
variation. Three replicates of each sample were run on the same plate and the procedure
was repeated 10 times. The inter-assay variation was evaluated by repeating 4 samples
(2 high, 1 intermediate, 1 negative) on 5 different days. The coefficient of variation (%
CV) from the replicates of each sample and between plates were then calculated 105.
Samples (Table 3.1) used to measure the sensitivity included sera from
experimentally infected foals (n= 21) from a previous study 106, mares vaccinated with
killed virulent R. equi (n=7), and a 3-month-old foal with rhodococcal osteomyelitis of
the phalanx. A group of foals diagnosed in the field with rhodococcal pneumonia based
on age, clinical signs and ultrasound of the thorax was also included, though definitive
diagnosis was not available (n=12).
To evaluate the specificity of the test, serum from a variety of horses exposed
to R. equi was used (Table 3.1): healthy newborn (<3d-old) foals post suckling as
previously described

107

, foals ranging from 2-4m of age euthanized for other reasons

that lacked pulmonary pathology and had negative lung tissue for R. equi, a control
yearling that had not exhibited clinical signs nor had ultrasonographic lesions of R. equi
45

as a foal, 3 adults and one 4-month-old foal with non- R. equi respiratory infections
(Streptococcus zooepidemicus pneumonia isolated from lung tissue or influenza
complicated with secondary bacterial infection other than R. equi diagnosed after
culture of transtracheal wash aspirate). Sera from broodmares in the Lexington, KY
area was also included. An additional group of sera collected from Icelandic horses
located in Iceland (n=10), where R. equi pneumonia has not been reported, were used to
evaluate VapA-specific IgG performance. To support the statement that R. equi
pneumonia does not occur in Iceland, records from all equine necropsies and cultures of
equine origin from the last 24 years performed at the Institute for Experimental
Pathology at the University of Iceland in Keldur, Iceland were examined. Moreover, to
rule out the possibility that antibodies were low in these horses due to some breedrelated inability of Icelandic horses to respond to R. equi, serum was collected from
Icelandic horses imported to the US (n=16) and from Icelandic horses born in the US
(n=12).
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Table 3.1 Number of horses included in the study and the median (range) ELISA Units
(EU) for each of the VapA-specific IgG subclasses evaluated. NT refers to samples that
were not tested.

Broodmares

97

VapA IgG
Median (range)
EU
2.3 (0.3-22.3)

Newborn foals post suckle

80

1.9 (0.9-10.3)

3.8 (1.2-27.9)

3.6 (2.2-47.4)

2.1 (1.9-2.7)

4m old foal no R. equi

1

2.6

2.1

1.9

2

Yearling no R. equi
Adults respiratory disease
(no R. equi)
Iceland

1

1.2

1.3

1.1

2.6

3
10

2.5 (2.5-3.4)
1 (1-1.3)

2.8 (2.4-3.4)
NT

3.3 (2.6-3.5)
NT

2.6 (2.6-5)
NT

Imported to the US

16

2 (1.2-10.6)

NT

NT

NT

Born in the US

12

2 (1.2-3)

NT

NT

NT

Mares vaccinated once

4

Mares vaccinated twice
Foals 8w post R. equi
challenge
3m old foal R. equi
osteomyelitis
Presumptive R. equi
pneumonia

3

74.4 (58-84)
338.3 (276-355)

47.2 (40-149)
91.5 (56.6-106.5)

72.9 (28-89)
291.6 (129-331)

2.9 (2.9-3)
1.9 (1.9-2.2)

2 (1-8)

4 (2-162)

3 (2-12)

3 (2-5238)

1

1.5

4.7

1.2

5737

12

2.5 (0.4-6.6)

7 (3-24.1)

1.9 (0.8-11.3)

10.4 (1.1-2439)

Positive

Icelandic

Negative

Sample

n

21

VapA IgGa
Median (range)
EU
1.9 (1.1-11.1)

VapA IgGb
Median (range)
EU
2.5 (1.4-12.1)

VapA IgG(T)
Median (range)
EU
2 (1.7-6.1)

Statistical analysis
The overall diagnostic performance of the ELISA for VapA-specific IgG
subclasses was assessed by the use of receiver-operating characteristic (ROC) curves

30

constructed using positive and negative foals. The cut-off value for each VapA-specific
ELISA was calculated using the results of the ROC curve distribution, which was based
on a combination of good sensitivity with high specificity 105. The area under the curve
(AUC) for each VapA-specific IgG subclass was determined using computer software
(SigmaPlotk). The AUC is a summary statistic of overall diagnostic performance. The
closer the AUC is to a value of 1, the higher the diagnostic value of the test 30.
The ability of VapA-specific IgG ELISA to differentiate between exposed and
non-exposed adult horses was evaluated using ROC curve analysis. In this case, a group
47

of broodmares and adult horses from Rhodococcus endemic farms in Lexington, KY,
were considered true positive (exposed) and a group of horses from Iceland were
considered true negatives (non-exposed).
Distribution of each data set was assessed using the Shapiro-Wilk normality
test. When variables were not Gaussian distributed non –parametric tests were used. To
compare ELISA units between populations, Kruskal-Wallis one-way ANOVA on ranks
and Mann-Whitney U tests were used. Pairwise multiple comparisons were performed
using the Dunn’s method. The analysis was performed 2-tailed and significance was set
at p<0.05.

Results
The intra-assay coefficient of variation (CV) and 95% confidence interval (CI)
are shown in table 3.2.

Table 3.2 Intra and inter-assay coefficient of variations (CV) and 95% confidence
interval for each VapA-specific IgG ELISA
Immunoglobulin
Intra-assay CV (95% CI)
Inter-assay CV (95% CI)
IgG
IgGa
IgGb
IgG(T)

8.1 (9.5, 6.7)
8.1 (9.6, 6.5)
10.3 (12.2, 8.4)
11.8 (15.9, 7.8)

10.6 (15, 6.1)
19 (27, 10.9)
13.4 (21, 5.8)
7.7 (10.1, 5.3)

As shown by the ROC curves (Figure 3.1), VapA IgG(T) significantly
(p=0.0001) outperformed the rest of the subclasses in identifying infected foals.
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Figure 3.1 ROC curve analysis of VapA-specific IgG subclasses. Foals with cultureconfirmed R. equi infection (n=21) were compared to clinically healthy 1-week-old
foals (n=80). The AUC (A) are shown in the graph. VapA-specific IgG(T) significantly
(p=0.0001) outperformed the rest of the IgG subclasses.

Based on the evaluation of the ROC curves for each VapA-specific IgG
subclass, the optimal cut-off for each ELISA was selected (Table 3.2) and the
corresponding sensitivity and specificity calculated. Based on these results, the
predictive value of a positive or negative test at various disease prevalence’s was
calculated only for IgG(T) (Figure 3.2).
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Table 3.3 Performance of each VapA-specific IgG subclass for foals with
experimentally induced R. equi pneumonia (n=21) and clinically healthy control foals
(n=80).
Area under ROC
curve (95% CI)
EU Cut-off
Sensitivity
Specificity
IgG
0.59 (0.45-0.73)
2.2
45
68
IgGa
0.58 (0.43-0.73)
3.8
19
56
IgGb
0.07 (0.28-0.57)
4.4
19
77
IgG(T)
0.99 (0.97-1.004)
2.7
90
96

Figure 3.2 Predictive value of a positive or negative test for VapA-specific IgG(T) at
various disease prevalences using a cutoff ELISA units ≥ 2.7. Foals with cultureconfirmed R. equi infection (n=21) were compared to clinically healthy 1-week-old
foals (n=80).

The test performance for each VapA-specific IgG subclass was evaluated using
a group of 2-5 month-old foals that were presumptively diagnosed with R. equi
pneumonia in the field (Table 3.4).
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Table 3.4 Performance of each VapA-specific IgG subclass for a group of naturally
infected foals with presumptive diagnosis of R. equi pneumonia (n=14) and clinically
healthy control foals (n=80).
Area under ROC curve
(95% CI)
EU Cut-off Sensitivity (%) Specificity (%)
IgG
0.52 (0.31-0.73)
2.2
43
74
IgGa
0.73 (0.57-0.89)
3.8
85
56
IgGb
0.13 (-0.03-0.3)
4.4
0
75
IgG(T)
0.78 (0.56-1.009)
2.7
79
100

Mares that were vaccinated using a killed R. equi bacterin had significantly
higher VapA-specific IgG (p<0.001), IgGa (p<0.001) and IgGb (p<0.001) than mares
that were not vaccinated (Figure 3.3). VapA-specific IgG(T) was not significantly
different between the two groups (p=0.16). Further, foals born from these vaccinated
mares had significantly higher VapA-specific IgG (p<0.001), IgGa (p<0.001) and IgGb
(p<0.001) than foals from unvaccinated mares; however levels of VapA-specific
IgG(T) were not different (p=0.07).

Figure 3.3 (Left) VapA-specific antibody response in vaccinated and unvaccinated
mares. (Right) VapA-specific antibody response in foals born from vaccinated and
unvaccinated mares. Asterisk (*) indicates statistical significance (p<0.001).
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Evaluation of the records from the Institute for Experimental Pathology at the
University of Iceland in Keldur, Iceland revealed that all 643 necropsies performed,
including 48 foals, were negative for macroscopic lesions consistent with R. equi.
Moreover, there were no positive isolates obtained from cultures from equine
origin.(Table 3.5) Sera from Icelandic horses that live in Iceland had significantly
(p<0.001) lower VapA-specific IgG than Icelandic horses imported to the US, Icelandic
horses and broodmares born in the US.(Figure 3.4) There was no significant difference
(p>0.05) between the VapA-specific IgG of Icelandic horses living in the US (imported
or born) and a broodmare population (p>0.05). VapA-specific IgG subclasses were not
evaluated further as Icelandic horses from Iceland had almost undetectable levels of
VapA-specific IgG. Based on these findings, Icelandic horses from Iceland are not
exposed to VapA+ R. equi and can be used as true negatives for differentiating exposed
from non-exposed adult animals. When this was done, VapA-specific IgG had high
sensitivity and specificity (Figure 3.5 and Table 3.6).

Table 3.5 Summary of the records from the Experimental Pathology at the University
of Iceland of which all were negative for R. equi.
Equine
Foal
Bacteriological samples
Period
necropsies
necropsies
(equine)
1990-2000
361
31
433
2001-2010
220
17
676
2011 to date
62
0
89
Total
643
48
1198
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Figure 3.4 VapA-specific IgG measured in Icelandic horses in Iceland (n=10), imported
from Iceland (n=16) and those born in the US (n=12). Also included for comparison is
a group of Thoroughbred mares (n=97). Populations with different letters are different
from each other at p<0.001

Table 3.6 Performance of VapA-specific IgG for exposed (n= 125) and non-exposed
(n=10) adult horses.
Area under ROC curve (95% CI) EU Cut-off Sensitivity Specificity
IgG
0.97 (0.94-1.002)
2.2
85
100
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Figure 3.5 ROC curve analysis of VapA-specific IgG. Non-exposed horses (n=10)
were compared to exposed horses (broodmares n=97, Icelandic horses imported to the
US n=16 and born in the US n=12). The AUC (A) from this analysis is shown.

Discussion
Although serology has been evaluated as a screening tool to detect early R. equi
infection, sensitivity has been reported to be low due to the antibody production that
results from exposure to environmental R. equi or from passive transfer 62,84,108. Further,
early methods failed to differentiate between pathogenic and non-pathogenic R. equi.
Here we have evaluated a VapA-specific ELISA for IgG and 3 different subclasses:
IgGa, IgGb and IgG(T). The VapA-specific ELISA has been widely used; however
62,66,75

information regarding its performance is incomplete. In our study, adequate

intra- and inter-assay CVs were obtained using this ELISA. Analytical specificity was
not tested as VapA is unique to R. equi having no known homologues in other bacteria
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109

. In addition, VapA+ has been identified in horse isolates but was absent in isolates

from bovine or pigs, which suggests host-driven exclusion of specific plasmid types 14.
A variety of samples have been previously used as negative controls for ELISA
specificity calculations. Adult horses have the disadvantage of possessing circulating
antibodies to VapA, likely in response to environmental exposure
newborn foals have also been used
to R. equi by colostrum occurs

66,85

24

85

. Sera from

; however passive transfer of maternal antibodies

and can result in high values. When these samples

were used as negative controls in our study, VapA-specific IgG and IgGb performed
poorly. VapA-specific IgGa had low sensitivity and specificity when young foals (<2m)
were evaluated after experimental challenge (data not shown), but the test performance
improved when older foals (>2m) were included. This finding was expected, as
endogenous production of IgGa requires time

70

. In contrast, IgG(T) had high

sensitivity and specificity for rhodococcal pneumonia in both young and old foals. This
IgG subclass has been reported to increase after experimental challenge
natural infection,

62

24,75

and after

though this is the first time that its appearance was evaluated as a

marker for disease. In contrast to the significant increase seen in VapA-specific IgGa
and IgGb after vaccination with killed R. equi, IgG(T) did not increase; as a result foals
born from these vaccinated mares had low IgG(T) levels. Immunoglobulin G subclasses
have been reassigned based on the IgG heavy chain constant gene region 110. In spite of
this, the new nomenclature has not been widely embraced; hence the original
nomenclature was used in this study. Additional work will be needed to similarly assess
all IgG subclasses, once these reagents become widely available.
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While VapA+ R. equi is considered an ubiquitous bacterium with world-wide
distribution

111

our results indicate it is likely not present in Iceland. The facts that

clinical cases of R. equi have not been reported in Iceland, characteristic lesions have
not been identified in necropsy, and the organism has not been cultured from tissues in
the past 24 years support this assumption. Since macroscopic lesions of rhodococcosis
are characteristic

25

and R. equi is easily isolated from tissues
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, it is unlikely that the

disease has been undetected. As shown by the antibody response in both imported and
Icelandic horses born in the US, this breed is capable of producing VapA-specific IgG.
To the authors’ knowledge, this provides the first serologic evidence that a group of
adult horses, living under natural conditions are unexposed to pathogenic R. equi. Using
sera from this true negative group of horses to establish a cut-off for the VapA-specific
ELISA, most US horses were positive, even when the overall level of antibodies was
quite low. A low level of VapA-specific IgG in adult horses has previously been
reported

66

and is likely a consequence of exposure to pathogenic R. equi in their

environment.
In conclusion, we confirmed that VapA-specific IgG subclasses, with the
exception of IgG(T), are poor predictors of disease due to the presence of antibodies
caused by environmental exposure. By contrast, VapA-specific IgG(T) had good
sensitivity and specificity in young foals. A limitation of this study is the lack of
definitive diagnosis of naturally infected foals; hence, further investigation of this test
under field conditions is needed.

Copyright © Macarena G Sanz 2014
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CHAPTER 4
ADMINISTRATION OF COMMERCIAL RHODOCOCCUS EQUI SPECIFIC
HYPERIMMUNE PLASMA RESULTS IN VARIABLE AMOUNTS OF IgG
AGAINST PATHOGENIC BACTERIA IN FOAL’S SERUM
Veterinary Record, in press (2014)

Summary
Rhodococcus equi is the most common cause of pneumonia in young foals. A
vaccine is not available and the use of R. equi specific hyperimmune plasma (HIP) is
common. Despite its widespread use, the efficacy of HIP in preventing disease remains
controversial. The objectives of this study were (1) to evaluate the virulence associate
protein A (VapA) specific IgG and IgG subclasses in commercially available R. equi
HIP and (2) to evaluate serum VapA-specific IgG and IgG subclasses in foals following
administration of commercial R. equi HIP.
Three different lots from 4 commercial R. equi HIP were sampled. VapAspecific IgG and IgG subclasses were evaluated in all samples using an ELISA. Serum
was collected from newborn foals either after commercial R. equi HIP was
administered (n=97) or not (n=70). Serum was also collected from each mare.
Administration of HIP significantly (p<0.001) increased VapA-specific IgGs in
recipient foals, however, there was a marked variation in VapA-specific IgGs in foals
receiving the same product. VapA-specific IgGs were significantly different (p<0.001)
between products and varied between lots, with coefficients of variation ranging from
17 to 123%. These results may explain previously reported disparities in HIP efficacy.
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Introduction
Rhodococcus equi (R. equi), a gram-positive facultative intracellular pathogen,
is the most devastating cause of pneumonia in foals between 3 weeks and 5 months of
age 1,87. Due to its worldwide distribution, this disease has a major financial impact on
the horse industry 2. Because of the absence of a vaccine to prevent R. equi infection,
intravenous administration of R. equi specific hyperimmune plasma (HIP) shortly after
birth is commonly practiced to reduce disease incidence or severity. This procedure
may be repeated 4-8 weeks later 48. The efficacy of this approach remains controversial
53,54,113

. Likewise, the protective component of R. equi HIP remains uncertain

53

.

Virulent R. equi carries a large virulence plasmid with a gene encoding for different
virulence-associated proteins (VapA, VapC to H). The vapA gene encodes for a
temperature inducible surface-expressed lipoprotein, which is necessary for R. equi
survival inside de macrophage

11,114

. Anti-VapA antibodies are thought to increase

opsonization of R. equi by phagocytes 51,61. Indeed, in vitro opsonization of R. equi with
immune serum enhanced phagolysosomal fusion and killing by macrophages 61.
Three R. equi HIP products licensed by the USDA for the aid in prevention or
moderation of R. equi pneumonia. Other products are also available for this purpose.
While R. equi HIP appeared to be effective in some field studies
experimental challenge

51,52

48-50

, others studies showed no positive effect

and after

53,54,113

. The

reasons for these disparate results are unclear. Differences in study design, clinical
outcome assessments, and timing of administration could explain the variability in the
reported efficacies. Extrapolation of experimental challenge data to natural disease is
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complicated by the variations in dosages and ages of foals used. Moreover, variability
in the plasma products and their distribution in the foals could affect the outcomes.
Therefore, the objectives of this study were: (1) to evaluate the distribution of
VapA-specific IgG and IgG subclasses in commercially available R. equi HIP and (2)
to evaluate VapA-specific IgG and IgG subclasses in foals after administration of
different R. equi HIP.

Materials and methods
VapA purification, source of reference control sera and ELISA – see Chapter 3

R. equi HIP
The uniformity of VapA-specific IgG and IgG subclasses in 4 commercially
available R. equi HIP namely: ImmunoGloa, ReSolutiona, EquiplasREAb and
PneumomuneRec was evaluated by testing 3 different lots of each plasma product. The
plasmas were thawed following manufacturer’s instructions and each bag was mixed
well prior to analysis by ELISA.

Serum
Sera were obtained from mare and foal pairs at farms that routinely
administered 1L of R. equi HIP to all foals within 24h of birth because of a history of
rhodococcal pneumonia and from a farm without a history of disease and therefore did
not use HIP. All mares and foals in a given farm were sampled. Mares were bled at the
time of foaling. Foals were included if they had adequate passive transfer. All foals on
the same farm received the same R. equi HIP product. Mares and foals were bled by
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venipuncture and serum samples were archived at -20°C for batch analysis. All foals
used in this study were born between January and May.

Statistical analysis
Data were analyzed using a commercial softwared. VapA-specific IgG
subclasses, expressed as ELISA units (EU), were compared using one-way ANOVA or
Kruskal-Wallis one-way ANOVA on ranks. Multiple comparisons were performed
using Dunn’s or Holm-Sidak methods, respectively. Significance was set at p<0.05.

Results
R. equi HIP
There were no significant differences between R. equi HIP products in terms of
IgG (p=0.54) or IgGb (p=0.21) content. There was a significant (p=0.008) difference in
VapA-specific IgGa between the plasmas. ReSolution had significantly more VapAspecific IgGa (p<0.05) than EquiPLasREA and PneumomuneRe, but it was not
different from ImmunoGlo. VapA-specific IgG(T) was extremely low in all products,
though ReSolution had more IgG(T) than PneumomuneRe (p=0.016) (Figure 4.1).
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Figure 4.1 (right) VapA-specific IgG, IgGa, IgGb and IgG(T) (left) in 3 different lots of
each R. equi HIP. The horizontal lines within each box plot correspond to each of the 3
bags of HIP tested for each company. R. equi HIP with different letters are different
from each other at p<0.05

The amount of variation between lots for each of the R. equi HIP varied
amongst the products tested. Overall, ReSolution had the lowest variation and
PneumomuneRe the highest (Table 4.1).

Table 4.1 Coefficient of variation (%) for VapA-specific IgG, IgGa and IgGb in
different commercial R. equi HIP.
CV%-IgG
CV%-IgGa CV%-IgGb CV%-IgG(T)
EquiplasREA

74.9

57.8

109.7

10.8

PneumomuneRe 123.8

106.6

112.9

7.3

ReSolution

17.2

27.8

35.7

19.8

ImmunoGlo

33.4

44.8

91.2

3.4
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Mares and foals
A total of 97 mare and foal pairs from 5 different farms that routinely used R.
equi HIP were evaluated. Mares (n=48) and foals (n=70) from a farm that did not use R.
equi HIP were included as controls. As expected, the foals receiving R. equi HIP had
significantly (p<0.001) higher VapA-specific IgGs than their mothers and foals that did
not received plasma.(Figure 4.2) VapA-specific IgG(T) was not evaluated after R.equi
HIP administration due to the overall low amount present in each of the products.

Figure 4.2 VapA-specific IgG (top), IgGa (middle) and IgGb (bottom) in mares at the
time of foaling, foals 24h after administration of R. equi HIP and foals that didn’t
receive any plasma 24h after birth. The horizontal line within the box represents the
median and the ends of the box represent the 75th and 25th quantiles. The whiskers
represent the upper and lower data points. The asterisk (*) indicates significant
differences (p<0.05).
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Administration of the different R. equi HIP to the foals resulted in significant
differences in VapA-specific IgG, IgGa and IgGb (p<0.001).(Figure 4.3) VapA-specific
IgG(T) in the foals was not evaluated after R.equi HIP administration due to the overall
low amount present in each of the products.

Figure 4.3 VapA-specific IgG (top), IgGa (middle) and IgGb (bottom) in foals 24h after
administration of different R. equi HIP products. Un-ID 1 and 2 refer to R. equi HIP
products whose source was not reported by the farm. The No HIP foals were untreated.
The horizontal line within the box represents the median and the ends of the box
represent the 75th and 25th quantiles. The whiskers represent the upper and lower data
points. Treatment groups with different letters are different from each other at p<0.05

As seen in Figure 4.3, a large variation in VapA-Specific IgG and IgG
subclasses was observed in foals receiving the same R. equi HIP product (Table 4.2).
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Table 4.2 Coefficient of variation (%) for VapA-specific IgG, IgGa and IgGb in foals
after R. equi HIP administration. The numbers shown are the result of the total variation
after 15% was subtracted to account for the variation of the ELISA.
IgG-CV (%)

IgGa-CV (%)

IgGb-CV (%)

PneumomuneRe

73

41

132

ReSolution

18

41

70

ImmunoGlo

46

65

43

Unidentified-1

151

113

133

Unidentified-2

64

94

95

Discussion
The rationale behind using HIP is to provide foals with R. equi-specific IgG,
along with other factors, which may enhance the humoral effector mechanisms against
this bacterium

58

. In this regard, IgG is the best known opsonin and acts on the initial

step of pathogen clearance 67. Thus, opsonising IgGs promote R. equi phagocytosis and
killing in vitro

65,66

. Likewise, R. equi HIP increased the oxidative burst activity of

neutrophils and macrophages and the release of the proinflammatory cytokine TNF-α
from macrophages in a dose dependent manner in vitro 63. VapA-specific antibodies, in
particular, have been shown to be important in adult horses 75, mice 115 and foals 51. As
expected, foals that received R. equi HIP had significantly more VapA-specific IgGs
than untreated foals. Surprisingly, there was a large variation in VapA-specific IgG and
its subclasses in foals receiving the same R. equi HIP product. Even when the interassay variability of the ELISA test was taken into account, the CV between the foals
remained large. Likewise, though body weights were not available for this study,
difference in foal size is low in thoroughbred

116

and unlikely to be the cause of the

differences seen here. Other unknown factors might account for the variability between
64

foals such as differences in the protocol for HIP administration between farms.
However, plasmas were kept in the freezer until administration, thawed following
manufacturer’s instructions and mixed before administration by the farm veterinarian.
Thus, differences within HIP products seem the more likely explanation. Indeed, the
amount of variation observed when different lots of the four R. equi HIP products were
evaluated was larger in some products than in others and reflected that seen in foals
following plasma administration. Furthermore, some of the foals that received R. equi
HIP had low amounts of VapA-specific IgGs that were similar to untreated foals.
Consistent with other reports

66

, mares also had an overall low level of VapA-specific

IgGs. This likely reflects the low numbers of R. equi in their environment. While this
low exposure resulted in a minimal antibody response in the mares, it was sufficient to
cause disease in foals on these farms. Indeed, low numbers of R. equi have been shown
to cause pneumonia in young foals after experimental challenge

106

. In the farms

included in our study, diagnosis of R. equi pneumonia was based on clinical signs, age
of the foal, thoracic ultrasonography and response to treatment. While this is common
practice in many farms 117 the lack of a definitive diagnosis limits the ability to evaluate
the significance of the variations detected in VapA-specifc IgG subclasses or the
protective effect of HIP.
There were also significant differences in VapA-specific IgG and IgG
subclasses in each product. Since the immunoglobulin subclass required for protection
against R. equi infection remains unknown, the clinical significance of this finding is to
be determined. However, the described protective activity of antibodies is a function of
their subclass. Thus, the use of R. equi HIP that contains inadequate quantity or quality

65

of VapA-specific antibodies could explain those instances when HIP fails to prevent R.
equi infection.
In conclusion, the variation seen in VapA-specific IgGs of R. equi HIP products
persists in foals after these products are administered. The variation is worse in some
products than in others. Given the lack of an effective R. equi vaccine 118,119, the cost of
R. equi HIP administration and its potential side effects, more work is needed to
identify the protective nature of HIP and to optimize its production to ensure better
product uniformity.

Copyright © Macarena G Sanz 2014
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CHAPTER 5
VAPA-SPECIFIC IgG AND IgG SUBCLASSES RESPONSE AFTER NATURAL
INFECTION AND EXPERIMENTAL CHALLENGE OF FOALS WITH
RHODOCOCCUS EQUI

Summary
Rhodococcus equi is a common cause of pneumonia in young foals worldwide,
however, the humoral response of foals to this disease remains poorly defined. VapA, a
bacterial lipoprotein, is the critical factor that differentiates virulent from non-virulent
R. equi. Therefore, the objectives of this study were to evaluate changes in VapAspecific IgG and IgG subclasses after experimental challenge of neonatal foals, as well
as after natural exposure and infection of thoroughbred foals on a breeding farm.
Two groups of foals were evaluated: (1) Foals experimentally challenged with
R. equi at 1 (n=18), 2 (n=4) and 3(n=6) weeks of age that were housed with confirmed
naturally infected (n=7) and not infected (n=3) foals. These foals were bled weekly for
a period of 8 weeks. (2) Thoroughbred foals routinely given 1L of R. equi
hyperimmune plasma (n= 106) and foals that did not receive plasma (n=35) were bled
at birth and monthly thereafter for a period of 4-5 months. Cases of rhodococcal
pneumonia amongst these foals were recorded.
Following birth, VapA-specific IgGs significantly (p<0.05) decreased in all
foals. Both VapA-specific IgGa and IgG(T) also decreased following birth and then
significantly increased (p<0.05) in those foals that developed rhodococcal pneumonia
after experimental and natural infection. However, VapA-specific IgGa also increased
over time after exposure to R. equi in foals that remained clinically normal. As a result,
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VapA-specific IgG(T) may be more useful in identifying foals affected with
rhodococcal pneumonia

68

Introduction
Rhodococcus equi is an important pathogen worldwide that causes severe
pneumonia

120

and a variety of extrapulmonary lesions in young foals

25,26

. In contrast,

adult horses are resistant to R. equi infection unless they are immunocompromised.
Nevertheless, little is known about the unique susceptibility of foals to this infection.
Protective immunity to R. equi likely involves innate, humoral and cell-mediated
58,66,121

. Antibodies, especially IgG, are important because of their

51,61,62,122

since entry of R. equi into macrophages mediated by Fc

immune responses
opsonic activity

receptors leads to enhanced bacterial killing

17,51,64,122

. Immunoglobulin G against R.

equi increased over time in foals beginning at 3-5 weeks of age as a result of natural
exposure 77,78. Oral and intratracheal inoculation of foals also resulted in an increase in
IgG

57

. None of these studies evaluated IgG subclasses of which there are multiple in

the horse with differing abilities to activate complement and stimulate a respiratory
burst from peripheral blood leucocytes 69. To date, little is known about the protective
role these IgG subclasses play in R. equi infection. Though previous studies also failed
to discount antibody responses to non-virulent R. equi, subsequent assays measuring
IgG to VapA, a surface lipoprotein of R. equi required for virulence

11,114

, allowed

differentiation between virulent and non-virulent bacteria. Nevertheless, there remains
uncertainty regarding the protective IgG response to R. equi. Thus, in adult horses
experimentally challenged with R. equi various subclass responses have been reported
including an increase in VapA-specific IgGa,

62

IgGb

74

or both IgGa and IgGb

75

. In

intrabronchial-infected foals there was an increase in VapA-specific IgGa and IgGb 74.
Whereas foals with naturally occurring rhodococcal pneumonia produced significant
69

amounts of VapA-specific IgG(T) 62. In contrast, a VapA-specific IgG(T) response was
not seen after natural exposure in adult horses or healthy foals

62

. However, VapA-

specific IgG(T) was significantly higher when a larger R. equi inoculum was used to
challenge neonatal foals

47

. Recently, VapA-specific IgG(T) was shown to be a good

indicator of rhodococcal pneumonia in a challenge of neonatal foals using a low dose of
R. equi which more accurately resembled natural infections

106,123

. While early R. equi

studies proposed that IgG(T) could not activate complement and therefore was an
undesired response to infection
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complement activator in horses

69

, it has since been shown to be the most potent

. Furthermore, Vap-specific IgG(T) increased after

oral immunization with virulent R. equi that successfully protected foals 24.
It is clear from the studies described above that further research needs to be
conducted in order to clarify the role of IgG and IgG subclasses in the response of foals
to R. equi. Also, an antibody response which differentiates R. equi exposure from
infection remains to be defined. Such knowledge is essential for the development of
preventive and diagnostic methods. Therefore, the objectives of this study were to
evaluate changes in VapA-specific IgG and IgG subclasses after experimental
challenge of neonatal foals, after natural exposure and after natural infection.

Materials and methods
VapA purification, source of reference control sera and ELISA – see Chapter 3

70

Serum samples
Sera from two populations of foals were included in this study: neonatal foals
experimentally challenged with R. equi and foals naturally exposed with or without
clinical signs of rhodococcal pneumonia. All sera were archived at -20°C for batch
analysis.
The challenged foals were intratracheally infected at 1, 2 or 3- weeks of age
(n=18, n=4 and n=6 respectively) with 103 cfu/foal of R. equi (206+UKVDL). The
challenge was performed for a previous study
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in which every foal was bled before

challenge and weekly thereafter until development of clinical signs of pneumonia or
until foals were 8 weeks of age. Another group of foals (n=10), that could not be
challenged due to partial failure of passive transfer (400 mg/dl<IgG < 800 mg/dl), was
housed in the same pasture as the challenged foals. Of these foals, those that developed
ultrasonographic and macroscopic lung lesions consistent with rhodococcal pneumonia
and had positive lung tissue culture for R. equi were considered naturally infected
(n=7). Foals that remained healthy thorough the duration of the study, did not develop
ultrasonogoraphic or macropscopic pulmonary lesions and had negative lung tissue
cultures, were considered not infected (n=3). All foals were bled at birth and weekly
thereafter for 8 weeks.
Sera from newborn foals at a thoroughbred farm that routinely administered 1L
of R. equi hyperimmune plasma (HIP) to all foals within 24h of birth (n=106) and from
farms that did not administer HIP (n=35) were used. Foals were included if they had
adequate passive transfer (IgG>800mg/dl) and were bled by venipuncture 24h after
birth or after HIP administration and monthly thereafter for a period of 4-5 months. A
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presumptive diagnosis of R. equi pneumonia was made if foals >1m of age developed
clinical signs of pneumonia (fever, lethargy, increased respiratory rate and effort, nasal
discharge, cough), had ultrasonographic lesions consistent with consolidation or
abscessation of the lung and responded to antimicrobial treatment for R. equi (rifampin
and azithromycin). A definitive diagnosis, by culture or PCR and cytology of a
transtracheal wash, was not performed.

Statistical analysis
Distribution of each data set was assessed using the Shapiro-Wilk normality
test. When variables were not Gaussian distributed non –parametric tests were used. To
evaluate changes over time, repeated measures ANOVA on ranks was used. To
compare ELISA unit (EU) results between populations, Kruskal-Wallis one-way
ANOVA on ranks and Mann-Whitney U tests were used. Pairwise multiple
comparisons were performed using the Dunn’s or Holm-Sidak methods. The analysis
was performed 2-tailed and significance was set at p<0.05. All data were analyzed
using a commercial software a.

Results
VapA-specific IgGs after experimental challenge: There was a significant
(p<0.05) decrease in all VapA-specific IgGs the first 2-4 weeks after birth in foals
challenged at 1, 2 or 3 weeks of age (Figures 5.1-3). After challenge of 1-week old
foals, a significant (p=0.003) increase was only observed for IgG(T) (Figure 5.1).
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VapA-specific IgGa increased over time, however it did not reach statistical
significance (p=0.054).

Figure 5.1 From top to bottom: VapA-specific IgG, IgGa, IgGb and IgG(T) expressed
as ELISA units (EU) over time after intratracheal challenge of 1-week-old foals (n=18)
with 103 cfu/foal of R. equi. The horizontal line within the box represents the median
and the ends of the box represent the 75th and 25th quantiles. The whiskers represent the
upper and lower data points. The asterisk (*) indicates significant differences with prechallenge (w1) values (p<0.05)

VapA-specific IgGa significantly increased over time after both, 2 and 3-weekold foals were challenged (p<0.05 and p=0.009 respectively) (Figures 5.2 and 5.3). No
other changes were seen in 2-week-old thorough the study whereas in the 3-week-old
foals there was a significant effect (p=0.028) of time on VapA-specific IgG
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concentration and a significant (p=0.002) increase in VapA-specific IgG(T) (Figure 5.
3).

Figure 5.2 From top to bottom: VapA-specific IgG, IgGa, IgGb and IgG(T) expressed
as ELISA units (EU) over time after intratracheal challenge of 2-week-old foals (n=4)
with 103 cfu/foal of R. equi. The horizontal line within the box represents the median
and the ends of the box represent the 75th and 25th quantiles. The whiskers represent the
upper and lower data points. The asterisk (*) indicates significant differences with prechallenge values (p<0.05)

74

Figure 5.3 From top to bottom: VapA-specific IgG, IgGa, IgGb and IgG(T) expressed
as ELISA units (EU) over time after intratracheal challenge of 3-week-old foals (n=6)
with 103 cfu/foal of R. equi. The horizontal line within the box represents the median
and the ends of the box represent the 75th and 25th quantiles. The whiskers represent the
upper and lower data points. The asterisk (*) indicates significant differences with prechallenge values (p<0.05)

VapA-specific IgGs in confirmed naturally infected foals: VapA-specific IgG
(p=0.03) and IgGb (p=0.004) significantly decreased over time in naturally infected
foals. VapA-specific IgGa significantly (p=0.006 increased over time towards the end
of the study. There was also a significant (p=0.027) increase of VapA-specific IgG(T)
over time (Figure 5.4).
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Figure 5.4 From top to bottom: VapA-specific IgG, IgGa, IgGb and IgG(T) expressed
as ELISA units (EU) over time in foals naturally infected with R. equi. The horizontal
line within the box represents the median and the ends of the box represent the 75th and
25th quantiles. The whiskers represent the upper and lower data points. The asterisk (*)
indicates significant differences with values obtained the first week of life (p<0.05).

VapA-specific IgGs in negative foals: Significant changes over time were not seen in
VapA-specific IgG (p=0.639), IgGa (p=0.676), IgGb (p=0.716) or IgG(T) (p=0.484) in
unchallenged foals that remained negative thorough the study.

VapA-specific IgGs in naturally exposed and presumptively infected Thoroughbred
foals: Rhodococcal pneumonia was diagnosed in 10 foals (10.4%) that received HIP
and in 5 (14.2%) that HIP was not administered. The median (range) age at the time of
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diagnosis was 62 days (42-91d) in foals given HIP and 119 days (35-150d) in the
untreated foals.
There were no significant differences in VapA-specific IgG (p=0.78), IgGa
(p=0.91), IgGb (p=0.84) or IgG(T) (p=0.48) immediately after HIP administration
between foals that remained healthy and those that later developed rhodococcal
pneumonia. All VapA-specific IgGs significantly (p<0.001) decreased over time after
HIP administration in foals that remained healthy thorough the study period. Similarly,
VapA-specific IgG and IgGb significantly (p=0.002) decreased in pneumonic foals;
though IgGa remained unchanged and IgG(T) increased over time but did not reach
statistical significance (p=0.06) (Figure 5 A-D).
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Figure 5.5 VapA-specific IgG (A), IgGa (B), IgGb (C) and IgG(T) (D) in foals that
develop pneumonia (____) or remained healthy (----) after HIP administration. The
horizontal line represents the mean and the whiskers are error bars. Each error bar was
constructed using the 95% CI of the mean. Time points with different letters are
significantly different between themselves in both groups. The asterisk (*) indicates
significant differences with values obtained at birth in healthy foals. The numeral (#)
indicates significant differences with values obtained at birth in pneumonic foals
(p<0.05).

There were no significant differences (p>0.05) in VapA-specific IgG, IgGa,
IgGb or IgG(T) at birth between foals not given HIP and remained healthy and those
that later developed rhodococcal pneumonia. Foals that remained healthy throughout
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the study had no significant changes in VapA-specific IgG (p=0.29), IgGa (p=0.4),
IgGb (p=0.5) or IgG(T) (p=0.4) over time. While VapA-specific IgGa (p=0.25) and
IgGb (p=0.07) did not change over time in foals that developed rhodococcal
pneumonia, VapA-specific IgG (p=0.006) and IgG(T) (p=0.006) significantly increased
in pneumonic foals thorough the study period (Figure 5.6 A-D).
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Figure 5.6 VapA-specific IgG (A), IgGa (B), IgGb (C) and IgG(T) (D) in foals that
develop pneumonia (____) or remained healthy (----) in farms where HIP was not
routinely administered. The horizontal line represents the mean and the whiskers are
error bars. Each error bar was constructed using the 95% CI of the mean. Time points
with different letters are significantly different between themselves in both groups. The
numeral (#) indicates significant differences with values obtained at birth in pneumonic
foals (p<0.05).
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Discussion
A better understanding of the humoral immune response of foals to R. equi is
necessary in order to develop new diagnostic tests and preventive measures. To date,
little is known about IgG and IgG subclass responses to R. equi infection in foals. Here,
VapA-specific IgG subclass responses were assessed in experimentally challenged,
naturally exposed, and infected foals. As expected, all foals showed a decreased in
VapA-specific IgGs during the first 2-4 weeks of life. This is consistent with the normal
decay of antibodies that occurs after passive transfer of immunoglobulins through
colostrum

70

. The VapA-specific IgG decrease was not as marked in foals diagnosed

with partial passive failure of transfer, likely owing to their overall lower plasma
antibody concentration.
Experimental challenge of neonatal foals using a low dose of R. equi, which has
been shown to result in slow, progressive disease similar to that of natural infection

106

,

resulted in a significant increase in VapA-specific IgGa and IgG(T) over time. Though
VapA-specific IgGa increased over time after challenge of 1-week-old foals, it did not
reach statistical significance (p=0.054).

This was due to the fact that endogenous

production of IgGa is not optimal until foals are 1m of age or older

70

and half of the

foals were euthanized early because they developed clinical signs. Should this group of
foals been followed for a longer period of time, a significant increase would likely have
been observed. Foals challenged at 2 and 3 weeks of age had a significant increase in
VapA-specific IgGa, indicating an enhanced ability to respond to this pathogen. Foals
are highly susceptible to rhodococcal pneumonia if challenged at 1 week of age but
developed resistance when challenged at 3 weeks of age
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, consistent with a

developing resistance mechanism. A significant increase in VapA-specific IgG(T) was
not seen in foals challenged at 2-weeks of age probably because only 4 foals were
included in this group, 2 of which were euthanized before they reached one month of
age as they developed clinical signs of pneumonia and synthesis of IgG(T) begins when
foals are somewhat older

70

. Similarly, VapA-specific IgGb did not increase after

experimental challenge in any of the foals as production of IgGb does not begin until at
least 8 weeks of age 70.
Comparably to that seen after experimental challenge, there was a significant
increase over time in VapA-specific IgG(T) after natural infection of foals with R. equi.
While an increase in IgG(T) over time was seen in pneumonic foals given HIP, this was
not statistically significant. One explanation may be that some of the foals were
misdiagnosed since culture and cytology of a TTW was not performed to obtain a
definitive diagnosis of R. equi. Indeed, 3 foals diagnosed as having rhodococcal
pneumonia showed no increase in VapA-specific IgGs over time, and therefore likely
had pneumonia of other origin. When these 3 foals were removed from the analysis
(data not shown), a significant increase in VapA-specific IgG(T) was observed over
time.
In general, VapA-specific IgG(T) significantly increased over time in foals that
developed clinical rhodococcal pneumonia while it remained lower in healthy foals.
This supports previous work showing that VapA-specific IgG(T) has high sensitivity
and specificity in detecting rhodococcal pneumonia in foals (Sanz et all, EVJ in press).
VapA-specific IgGs did not increase in control foals that were confirmed negative by
ultrasound and at necropsy. However, it did in healthy thoroughbred foals, though this
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was not statistically significant. It has been previously shown that VapA-specific IgG
does increase over time in healthy foals as a result of natural exposure to R. equi

84

.

Routine thoracic ultrasonography was not performed in the thoroughbred foals,
hence subclinical disease cannot be ruled out.

Indeed, the majority of foals that

develop pulmonary lesions resolve them without the need for treatment 32.
In conclusion, the early response to R. equi infection is characterized by an
increase in VapA-specific IgGa and IgG(T) that is seen as soon as 4-5 weeks of age.
This increase in VapA-specific IgG(T) is more specific for R. equi infection as IgGa
also increases significantly as a result of environmental exposure, hence its evaluation
may become useful to differentiate rhodococcal pneumonia from other bacterial
pneumonias affecting young foals. Further research is needed to evaluate the role of
VapA-specific immunoglobulins in subclinical cases, in particular more work is needed
to evaluate the use of VapA-specific IgG(T) as a possible marker for disease. The
similarities observed between the IgG response of foals after experimental challenge
and natural infection confirms that the use of a low dose of R. equi to challenge foals is
an appropriate model to study the humoral response to this disease.
Copyright © Macarena G Sanz 2014
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CHAPTER 6
CONCLUSIONS, FUTURE DIRECTIONS AND LIMITATIONS

While R. equi pneumonia is a common cause of pneumonia with devastating
consequences for the equine industry, much remains unknown about the reasons for the
foal’s unique susceptibility to this pathogen. As a result, attempts to develop
prophylactic methods have not been successful. The development of the unique
neonatal foal model described here, that results in slow progressive disease and
regression in approximately 50% of the foals, provides a new tool to advance the
understanding of the immune response and the individual susceptibility of foals to R.
equi. While is accepted that foals are infected with R. equi shortly after birth; the
duration of their susceptibility has not been well quantified. This model developed here
provided the means to systematically evaluate the effect of age on susceptibility and
showed that the window for disease occurs within the first month of age. These findings
have a direct implication on the future approaches to prophylaxis.
Diagnosis of the early stage of R. equi pneumonia remains a challenge for the
equine practitioner. Culture and cytology of lung fluid are not useful until foals are
clinically ill. Thoracic ultrasonography over-estimates the prevalence of disease and
results in excessive antimicrobial use. The results on chapters 3 and 5 identify VapAspecific IgG(T) as a potential marker for disease after the ELISA was validated. Its
measurement in foals showing clinical signs of pneumonia may provide an innovative
tool to confirm or rule out R. equi as a causative agent, especially as this will only
require a serum sample instead of the more invasive TTW for culture. The possibility to
rule out R. equi with a simple test will aid in the decrease of macrolide use in foals and
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the development of resistance to this drug, something that is currently a concern among
equine practitioners. More research is needed to evaluate this immunoglobulin’s ability
to predict clinical disease and its correlation with the degree of pneumonia in both,
clinical and subclinical foals.
This study evaluated, for the first time, the VapA-specific IgG status of a group
of Icelandic horses and found that horses in Iceland are not exposed to virulent R. equi,
probably a result of low or absent amounts of this organism in the environment. The
northern location of this island with its cold weather and the fact that in 982 AD the
Icelandic parliament passed laws prohibiting the importation of horses into Iceland are
factors that contribute to the lack of rhodococcal cases reported in this country. The
availability of this naïve population provides a valuable source of true negative animals
to establish assay baselines. Using these horses, an ELISA for VapA-specific IgG and
IgG subclasses were validated and used to follow the changes that occur in these
antibodies after natural exposure, natural infection and experimental challenge. This
knowledge will be helpful in evaluating responses to vaccination or other prophylactic
measures. The ELISA was also used to detect the surprisingly high variability of VapAspecific IgGs in commercial HIP, which was reflected in the variability seen in foals
after HIP administration. Such variability may explain controversial reports on the
efficacy of HIP products in prevention of R. equi pneumonia. Further work is needed
evaluating HIP production and processing to improve product quality and uniformity.
A limitation of this work was the use of a single R. equi strain in the
experimental challenge model. The strain selected originated from a field case of
rhodococcal pneumonia near Lexington, KY, hence it is considered of clinical
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relevance. Another limitation is the small number of foals used in each experiment, a
common theme in equine research because of cost and animal availability.
Acknowledgment of this limitation is important for interpretation of the results reported
here. Lastly, only VapA-specific IgG subclasses were evaluated in the HIP study. At
this point, the protective component, if any, of HIP remains unknown; however, VapA
antibodies are considered important. More field work is needed in this area to evaluate
the observed variability in HIP lots and its impact in protection against R. equi.
Overall, this body of work has resulted in a consistent challenge model that
closely resembles natural disease. It has also confirmed the effect of age in foal
susceptibility and has been effective in describing the VapA-specific IgG and IgG
subclass response of foals to R. equi, not only after infection but also after natural
infection. As such, this work will aid future research on prophylactic strategies and
their timing, which hopefully will result in a better knowledge of this common but still
poorly understood condition.

Copyright © Macarena G Sanz 2014
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APPENDIX
Manufacturers’ details – Chapter 3
a

Amersham Pharmacia Biotech, Pittsburgh, PA, USA.

b

Bio-Rad, Philadelphia, PA, USA.

c

MgBiologics, Ames, IO, USA.

d

Plasvacc USA Inc, Templeton, CA, USA.

e

Thermo Scientific, Rochester, NY, USA.

f

Sigma Aldrich, St. Louis, MO, USA.

g

Jackson ImmunoResearch, West Grove, PA, USA.

h

Bethyl Laboratories, Inc, Montgomery, TX 77356 USA

I

Beckman Coulter, Brea, CA, USA.

j

KPL, Gaithersburg, MD, USA.

k

SigmaPlot, SPSS Inc., Chicago, IL, USA.

Manufacturers’ details – Chapter 4
a

MgBiologics, Ames, IO, USA.

b

Plasvacc USA Inc, Templeton, CA, USA.

c

Lake Immunogenics Inc, Ontario, New York, USA.

d.

SigmaPlot, SPSS Inc., Chicago, IL, USA.

Manufacturers’ details – Chapter 5
a

SigmaPlot, SPSS Inc., Chicago, IL, USA.

87

Chapter 1
Supplementary Table 1.1 Comparison of the original and current nomenclature for
equine IgG subclasses.68
Original Nomenclature

Current Nomenclature

IgGa

IgG1

IgGb

IgG4 and IgG7

IgG(T)

IgG3 and IgG5

IgGc

IgG6
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Chapter 2

Supplementary Figure 2.1 Study design for foals challenged intratracheally with
doses of R. equi ranging from 106 to 102 cfu/foals (top) and with 103 cfu/foal at
different ages (bottom).

Supplementary Figure 2.2 One-cm3 tissue samples were obtained for bacterial
89

culture. Samples were routinely collected from the cranial lobe, cranio-ventral and
dorsal border of the diaphragmatic lung lobe of each lung and from the accessory lobe
(not in the picture)

Supplementary Figure 2.3 Serial dilutions (not diluted to 1:10000) of the
supernatant obtained after tissue homogenization plated onto TSAYE plates. Plates
were incubated at 37 ºC for 48h and the number of colonies/g of tissue was then
calculated. Colonies were observed for typical R. equi characteristics (large, mucoid
colonies that developed a red pigment over a 72h period)
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Protocol 2.1 - Preparation of R. equi inoculum for foal challenge (Figures A
and B)
1.From -80C stock solution streak 2 TSAYE plates
2.Incubate at 37ºC for 48h
3.Take a single colony with a sterile loop and inoculate 4ml of TSBYE broth. Repeat 4
times using different colonies. Gram stain colonies and evaluate colony morphology
for characteristics (mucoid, large, pink)
4.Incubate at 37ºC for 48h
5.Evaluate OD600: ~0.38-0.44
6.Select the broth with OD600 0.4 or closer. This is the broth that will be used for
challenge.
a- Perform 5 serial dilutions (1:10), plate 25 ul of the 10-5 and spread for bacterial
counting, in duplicate. Incubate at 37ºC for 48h to evaluate purity of the culture
and count colonies.
To calculate the concentration of the broth:
cfu counted (average of both plates) x 40 = cfu x10-5/ml
b- Submit an aliquot to the UKVDL for PCR confirmation of R. equi and VapA
c- The concentration of the broth with OD600 = 0.4 is 107/ml (this is based on the last
3 years of isolation, this has remained constant and we have done this weekly).
Perform serial dilutions on PBS to obtain the desired concentration for challenge

Figure A Frozen stock to broth stock
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Figure B Challenge inoculum preparation, cfu count, VapA confirmation
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Chapter 3
Protocol 3.1 - VapA purification from Vap-containing E. coli
E. coli proliferation
1. Scrape small amount (VAP)-containing E. coli cells’ glycerol stock onto one LB
agar plate containing 100 ug/ml Ampicillin
2. I
3. Touch single colony and inoculate a 5 ml culture of LB broth containing 100 ug/ml
Ampicillin [Repeat for total of 4(5 ml) cultures]
4. Incubate for 5 hours in 50 ml conical tubes with lid slightly
shaking at ~150 rpm
5. Add 5 ml starter culture to 500 ml LB broth containing 100 ug/ml Ampicillin (One5 ml culture per 500 ml broth) (Culture minimum of three flasks)
6. Incubate overnight
loosened or with filter top on flask.
7. Remove cultures from shaker. Check that OD600 is around 1.0. If culture has not

8. Add IP

(See

page 106 of protocol for IPTG formulation)
9.
production. (150 rpm)
10. Spin down cultures @ 7700g for 10 minutes. (or 2500g for 45-60 minutes at 4
11. Pour off supernatant and remove a sample for analysis at a later time.
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)

12. Resuspend the pellet in a total volume of 25 ml sterile PBS and place 25 ml in 50
ml centrifuge tubes with lid slightly loosened into –

freezer overnight (a

freeze/thaw)
13. Perform purifications using Purification of GST Fusion Proteins protocol (see
below)
II- Purification of GST (glutathione S-transferase) fusion proteins – VapA
Day one
Sonicate cells in centrifuge tubes for 30 sec pulses (x 4 times) keeping the samples on
ice.
1. Add Triton X-100 (20% stock solution) to make 1% (1 ml per 20 mls) (See page
106 of protocol for formulation).
a- Mix in the plate rocker gently for 30 min @ room temp.
b- Spin @ 10,000 rpm for 10 min @ 4oC.
2. Remove and save supernatant in 50 mL conical tube (aliquot a sample for SDSPAGE) (See pages 97-103)
a. Pool supernatants.
b. Suspend pellet in minimal PBS, pool and aliquot a sample for SDS-PAGE. (Only
once at the beginning of the study)
c. Filter supernatant (Steriflip 100 m vacuum flip filter- Millipore Cat no.
SCNY00100).
3. Add 3.5 ml of pre-washed Glutathione Sepharose beads* (mix with PBS in the
column) to the 50ml supernatant to use the big column.
4. *Pre-Washing procedure: (If using for the first time)
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a- Pipette 1 ml of sterile PBS in column (Thermo disposable plastic columns with a
filter disc-29920, 29922, and 29924) and add 1.33 ml of beads (75% slurry in
ethanol).
b- Remove cap and wash beads by running 10 ml through column.
c- Cap off bottom and add 1ml PBS (50 % slurry), 2 ml total.
d- Using a Pasteur pipette, add to the 50 mls of supernatant in the conical tube.
e- Place parafilm on the top and bottom cap of the column to prevent drying.
5. Incubate overnight with gentle mixing @ 4oC. (Fusion protein binds to beads)

Day two (work at room temperature)
1. Let the beads settle and add top portion to the column first (faster), and finally the
beads in PBS. Collect a sample for SDS-PAGE.
2. Wash beads gently twice (two columns full) with sterile cold PBS. Cap bottom of
the column. Collect a sample for SDS-PAGE
3. Add 50 ul thrombin (GE Healthcare GST Gene Fusion System Handbook Chapter
6) to 950 ul PBS and add to column. (Wrap parafilm around top and bottom caps of
column)
4. Incubate overnight (22 hours) @ room temperature with gentle mixing. (Thrombin
cleaves protein).

[Alternative method (faster)]:
1. Spin beads in 50 ml conical tube at 4 oC at 2500-3000 rpm for 5-7 minutes, aspirate
fluid off and add to column leaving beads in tube.)
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2. Wash beads gently twice (two columns full) with sterile cold PBS. Centrifuge as
above between washes.
3. After final wash, add beads to column, allow to drain, and cap bottom of the
column.
4. Add 50 ul thrombin (GE Healthcare GST Gene Fusion System Handbook Chapter
6) to 950 ul PBS and add to column (i.e. 50 units per 1 ml of beads). Place parafilm
around top and bottom caps of column.
5. Incubate overnight (16 hours) @ room temperature with gentle mixing. (Thrombin
cleaves protein).

Day three
1. Remove top and bottom caps and collect the protein (approx. 500 ul) into a small
sterile tube. (Place on ice until ready to run Bradford, and then freeze at -80oC)
Replace tip on bottom and lid on top of column. If beads become trapped in the lid,
the protein will be removed in the next step.
2. Add 2 mls of PBS to column and gently mix on tilt table for 30 min @ room
temperature. Collect eluate and place in a separate tube. Place on ice until ready to
perform Bradford assay, then freeze at -80oC. This portion usually needs to be
concentrated (see comment below).
3. Remove a sample of the eluate for SDS-PAGE (for verification of protein).
Replace caps on column with sterile PBS to store in fridge until ready to clean and
regenerate column, as below.)
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If necessary, concentrate proteins using first the 30,000 NMWL filter, then filter flow
through w/ 10,000 MWCO keeping retentate. Centrifuge at 4oC for 5-20 minutes
depending on volume at 3,000 g.

Clean and regenerate column for further use:
I.

Remove GST from beads by adding 1 ml of glutathione elution buffer (See page
108 for formula). Mix for 10 min @ room temperature.

II.

Elute and wash several times with PBS. (Repeat twice saving eluate in separate
tubes for Bradford analysis of protein amount, when initially checking protocol).

III.

Wash with 1 ml of 0.1M Tris HCl + 0.5M NaCl, pH 8.5, Followed by (1 mL) 0.1M
sodium acetate + 0.5M NaCl, pH4.5 (See pages 107-108 for formulas)

IV.
V.

Repeat wash cycles 4 times, alternating buffers.

VI.

Wash with 2 mls PBS.
Replace top and bottom caps, add 1ml PBS, and seal with parafilm. For long-term
storage or further information regarding regeneration, refer to page 29 of the kit
instruction booklet (GE Healthcare GST Gene Fusion System Handbook- Chapter 4
batch purification).
Run Bradford assay to quantify proteins. (See page 105) Store at -80oC until ready to
use.
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SDS-PAGE gel with Coumassie Blue staining
Sensitivity=.1-.5 ug (50-100 ng/band)\
For purified sample- want 10 ug, for other samples 50-100 ug, adjust volume w/PBS
Laemmli Sample buffer-2x sample buffer 475 ul + 25 ul 2-me ( -mercaptoethanol)

For 30 ul volume for 18 well gel- 15 ul of sample+ 15 ul 2x sample buffer w/2-me
For 40 ul volume for 12 well gel- 20 ul of sample+ 20 ul 2x sample buffer w/2-me
1. Mix well
2. Heat to 95oC for 5 minutes
3. Place on ice to cool
4. Centrifuge several seconds (5 min at 6.0 rcf)
5. Place at -80 oC for storage if not using immediately
Marker:

1μL + 20 μL reduced Laemmli buffer;
Heat to 95oC for 5 minutes;
Place on ice to cool;
Load 10 μL/ well.

Molecular Weight: 200 KD; 116.2; 97.4; 66.2; 45; 31; 21.5; 14.4; 6.5.
Purchase a pre-poured gel
Biorad Criterion 4-20% Tris-Hcl gel with 14 or 18 wells
(Biorad Labs, 2000 Alfred Nobel Dr. Hercules, CA 94547)

Loading the gel
1. Remove the white tab from the bottom of the gel.
2. Carefully remove the comb.
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3. Use a syringe with a needle attached to flush the wells with running buffer just
before loading to get rid of any unpolymerized polyacrylamide that may seep in.
4. Insert the gel into the apparatus with the numbers facing outward.
5. Pour Tris-glycine electrophoresis buffer into the upper and lower chambers. Fill to
within several mm of top and to the second line in the bottom chamber. Make 500
ml of running buffer by adding 100 ml of 5X stock to 400 ml Ultrapur H20.
6. When loading the gel, load something (1X loading buffer in blank lanes) in every
lane and the dye will migrate more evenly.(Use SDS Standard, Broad Range,
catalog # 161-0317 as size marker)-molecular weight markers
7. Start large thin gels at a constant current of 15 mA/gel for 10 minutes then increase
to 20 mA/gel for the remaining time. (Check in 1½ hrs)

Where you stop the gel will depends on how big the smallest protein is that you want to
visualize. It should take about 2 1/2 – hours for a large, thin gel to run. A thick gel
could take 6 - 7 hours. Run minigels at 15 mA. It should take about an hour to run.

Staining the gel
1. Turn off machine and remove the lid
2. Pour off buffer from top chamber
3. Use lid to break open the gel chamber
4. Cut off the wells
5. Pull gel off from the bottom by lifting center with forceps and running fingers to
edges (Bottom is tougher than the top)
6. Place gel in plastic lid and cover with Coumassie Blue stain.
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7. Place on rocker and rock (setting 3) for ~45 mins.
8. When finished, pour Coumassie Blue back into container for reuse.
9. Move gel to a sealable Tupperware container.
10. Add wash (7% Acetic Acid, 10% methanol- 70 ml AA + 100 ml methanol, bring to
1L with ultrapur H20).
11. Add a sponge to the top of the liquid (helps to bind the Coumassie Blue)
12. Place on gentle rocker.
13. Change wash ~every 30 mins until you go home.
14. Allow to rock (wash) overnight

Tris-Glycine Electrophoresis Buffer
5X Stock:
15.1 g Tris base + 94 g glycine + 900 ml H2O
Then add 50 ml of 10% electrophoresis-grade SDS, and adjust volume to
1000 ml with H2O

For buffer to add to the apparatus:
Make 500 ml by adding 100 ml of 5X stock to 400 ml Ultrapur H20
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To visualize/photograph gel:
After overnight wash, place gel on saran wrap. Place on white light on transilluminator
to visualize. Then move to transilluminating reader. Settings: 10 ms, no filter, adjust as
necessary. Change aperture to get a better picture.
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SDS-PAGE gel with Silver staining
Sensitivity= .25 ng/band; 50 ng/well

For purified sample- want 10 ug, for other samples 50-100 ug, adjust volume w/PBS
Laemmli Sample buffer-2x sample buffer 475 ul + 25 ul 2-

-mercaptoethanol)

For 30 ul volume for 18 well gel- 15 ul of sample+ 15 ul 2x sample buffer w/2-me
For 40 ul volume for 12 well gel- 20 ul of sample+ 20 ul 2x sample buffer w/2-me

1. Mix well
2. Heat to 95oC for 5 minutes
3. Place on ice to cool
4. Centrifuge several seconds
5. Place at -80 oC for storage if not using immediately

Purchase a pre-poured gel
Biorad Criterion 4-20% Tris-Hcl gel with 14 or 18 wells
(Biorad Labs, 2000 Alfred Nobel Dr. Hercules, CA 94547)

Loading the gel
1. Remove the white tab from the bottom of the gel.
2. Carefully remove the comb.
3. Use a syringe with a needle attached to flush the wells with running buffer just
before loading to get rid of any unpolymerized polyacrylamide that may seep in.
4. Insert the gel into the apparatus with the numbers facing outward.
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5. Pour Tris-glycine electrophoresis buffer into the upper and lower chambers. Fill to
within several mm of top and to the second line in the bottom chamber. Make 500
ml of running buffer by adding 100 ml of 5X stock to 400 ml Ultrapur H20.
6. When loading the gel, load something (1X loading buffer in blank lanes) in each
lane and the dye will migrate more evenly. (Use SDS Standard, Broad Range,
catalog # 161-0317 as size marker). Molecular weight markers
7. Start large thin gels at a constant current of 15 mA/gel for 10 minutes then increase
to 20 mA/gel for the remaining time. (Check in 1½ hrs).

Staining the gel
A- Silver Staining the gel (Pierce Silver Stain Kit 24612) - use constant gentle
shaking
1. Turn off machine and remove the lid (Use lid to break open the gel chamber)
2. Pour off buffer from top chamber and cut off the wells
3. Pull gel off from the bottom by lifting center with forceps and running fingers to
edges (Bottom is tougher than the top)
4. Place gel in plastic lid and wash for 5 min in ultrapur H20. Twice
5. Fix gel for 15 min in 30% ethanol : 10% acetic acid soln. twice
6. Wash gel for 5 min in 10% ethanol twice
7. Wash for 5 min in ultrapur H20 twice
8.

20)

9. Wash for 1 min in ultrapur H20 twice
10.
11. Wash for 20 sec in ultrapur H20 twice
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12. Develop gel for 2Developer)
13. Stop with 5% acetic acid for 10 min.

B- GelCode Blue Stain Reagent (Supplemental Figure 3.1)
Directions:
1- Wash gel three times with deionized water (15 minutes);
2- Add GelCode Blue Stain Reagent (1 hour);
3- For increase clarity, use the optional water wash enhancement step (1 hour).

Supplemental Figure 3.1 Gel stained using GelCode blue stain. The marker is on the
left of the gel and the size of each band is indicated (from 200 KDa to 6.5). The
recombinant VapA protein (arrow) is identified between the 14.4 and the 21.5 marker.
The size of the VapA is slightly larger as a small piece of the GST tag remains attached
after protein purification (natural size of VapA is 14-17KDa)
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Recipes

Running buffer
Make 500 ml by adding 100 ml of 5X stock to 400 ml Ultrapur H20

Silver Stain
30 ml ethanol + 10 mil glacial acetic acid + 60 ml H20*
10 ml ethanol + 90 H20*
Sensitizer 50 ul in 25 ml H20
Enhancer 500 ul in 25 ml stain
Developer Work solution 500 ul enhancer in 25 ml developer
5 ml glacial acetic acid + 95 ml H20*
* = can be made in advance

5X TBE for 1L
54 gm Tris Base
27.5 gm Boric Acid
40 ml 0.25 M EDTA pH 8.0

Use @ .5X for agarose gels
1x for polyacrylamide gels
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Bradford Assay Protocol
Make standard using BSA at 1 mg/ml stock solution. Make 1:10 dilutions and perform
in singlets.

Sample= 200 ul Bradford solution + 800 ul ultrapur H20 + 10 ul sample (protein)
If sample turns dark or bright blue when you add the sample to the Bradford solution,
the concentration is too high and you need to perform a 1:10 dilution of the sample.

Standard must go through 0 or it is not able to measure low concentrations
Thaw protein samples on ice.
Read on spectrophotometer using “Bradford” settings. First tube is always the blank

The protein binds the Coumassie and forms a precipitate. The precipitate settles out and
you get an erroneous reading. Therefore, you must work quickly.
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Chemicals

at -20oC
100ug/ml = 2 ml Amp/500 ml broth, .5 ml Amp/125 ml broth, 20 ul Amp/5 ml broth
50 ug/ml= 1 ml Amp/500 ml broth, .25 ml Amp/125 ml broth, 10 ul Amp/5 ml broth

IPTG (isopropylthio-beta-D-galactoside)- BP1620-10 Fisher Scientific- keep in
desiccator in -20oC freezer
40 mg/ml 1250 ul per 500 ml bacteria
1 g =25 ml=20 tubes of 1250 ul
10 g=250 ml=200 tubes of 1250 ul; 50 tubes of 5 ml
Allow to warm to room temperature, soluble in H20
In Chemical Fume Hood- Use ultrapur H20 25 ml + 1 g powder. Vortex to mix.
Store aliquots in -20oC

PMSF (phenylmethylsulfonyl fluoride- protease inhibitor)- .44 g in 25 ml ethanol = 100
mM stock- In Chemical Fume Hood- remake fresh every 6 weeks- loses potency. Store
in fridge.

Triton-X-100 20% stock solution to a [final] of 1% when added to the solution. (1ml
per 20 ml; 1.25 ml per 25 ml) Store in fridge.

Thrombin (GE Healthcare product # 27-0846-01)- add 500 ul ultrapur H20 to bottle and
aliquot in 50 or 100 ul volumes; store at -80oC
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1M solutions = Dry= M x MW x V= g
Hydrated= M x V x # H20 x 18.015 = ml H20 contributed by hydrated compound.

1) Tris Base MW=121.14
For 100 ml
= 121.4 x 1M/1 x 100/1000 ml
= 12.114 g Tris Base →dissolve in ~60 ml H20
pH to 8.5 w/concentrated HCl to make Tris HCl
Adjust final volume to 100 ml with H20 (1)

2) 1 M NaCl MW= 58.44
For 200 ml
=58.44 x 1M/1 x 100/1000 ml x 2
=5.844 g x 2 dissolved to a final volume of 200 ml H20
=11.688 in 200 ml H20 (2)

Add 10 ml 1M TrisHCl + 50 ml 1M NaCl, bring to 100 ml w/ H20

(3)

.1 M Na Acetate (Trihydrate) [CH3COONa∙3H20 MW 136.08] + .5M NaCl pH 4.5
100 mM stock NaAcetate=1.36 gm in 100 ml H20

1.36gm NaAcetate + 50 ml 1M NaCl, adjust pH w/glacial acetic acid to 4.5
Bring to 100 ml w/H20 for 100 mM stock

(4)
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Glutathione elution buffer (200 ml)
=307.3 x 10mM/1000 x 200ml/1000
=0.615 g glutathione = 10 mM
50 mM Tris=50/1000 x 200/1 =10 ml 1M Tris pH 8.5

Add 100 ml H20 and dissolve .615 gm glutathione, add 10 ml 1 M Tris (pH 8.5)
Adjust pH to 8.0 with HCl; adjust volume to 200 ml with H20

(5)

Molecular weights
KCl – 74.56
KH2HPO4– 136.09
Na Acetate – 136.08
Na2HPO4– 141.96
NaCl – 58.44
MgCl – 95.21
Reduced Glutathione - 307.3
Tris Base -121.14
Protocol 3.2 – VapA-specific IgG and IgG subclasses ELISA
Materials
Coating: Coat @ 0.5 ug/well for VapA over night @ 4ºC. Mix vapA with coating
buffer)
Blocking Buffer: Prepare 1% PVA block by mixing 1g PVA and 100mL ddH2O; heat
and stir until dissolved (about 45 min)
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Just before use dilute 1% PVA with PBS (1:1)
Samples: Dilute samples at 1:100 with ELISA Wash Buffer
Secondary antibody: Add 1uL goat-anti-horse IgG in 10mL Elisa wash (Peroxidase –
conjugated AffiniPure Goat Anti-Horse IgG; Jackson Immuno Research, West Grove,
PA)

Procedure
1- Add 100uL vapA coating solution per well. Refrigerate plate over-night.
2- Wash plate 3 times with Washing Buffer, 300 ul per well.
3- Add 200uL Blocking Buffer per well. Incubate 1 hr at RT on bench top.
Note: Dilute Blocking Buffer before usage 1% PVA with PBS (1:1)
4- Wash plate 3 times.
5- Add 100uL diluted serum samples (duplicate). Incubate 1 hr at 37ºC.
6- Wash 3 times
For total IgG go to step 7, for specific R. equi istotype Ig test go to setp 8
7- Add 100 ul secondary antibody (1:10000 dilution in washing buffer. Rabbit antiHorse IgG-Peroxidase, Sigma Aldrich-A9292). Incubate for 1 hr at 1 hr at 37ºC.
8- Add 100 ul of secondary of mouse anti-horse IgGa, IgGb and IgGT, incubate 1
hr at 37ºC.
IgGa dilute at 1:100 in Washing Buffer for old supernatant. New hybridomas 1:2
IgGb dilute at 1:10 in Washing Buffer (both old and new)
IgGT dilute at 1:10 in Washing Buffer. New hybridomas 1:5
9- Wash 3 times
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10- 3rd Ab, HRP conjugated Goat anti-mouse Ig (1:2000 dilution in washing buffer,
Goat anti-mouse IgG, Jackson ImmunoResearch, 108-035-003), add 100ul/well,
incubate 1 hr at 37ºC.
11- Wash 3 times
12- Add 100uL SureBlue, incubate for 5 min keep out of light.
13- Add 100uL Stopping solution.
14- Read immediately at A450 nm and A630.
Standard Curves
Total IgG and IgGa: Use Mg Biologics R equi plasma. Start curve on 1:90 using a 1:3
dilution factor. Seven points from there (to 1:65610)
IgGb: Use Mg Biologics R equi plasma. Start curve on 1:270 using a 1:3 dilution
factor. Seven points from there (to 196830)
IgG(T): Use Plasvaac R equi plasma. Start curve on 1:16 using a 1:2 dilution factor.
Seven points from there (to 1:1024)
Note: Need a positive and negative controls, Blank, no VAP, no serum, no 2ndAb, no
3rd Ab on a plate every time ELISA is run
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